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INTRADERMAL DELIVERY OF PLASMIDS ENCODING ANGIOGENIC GROWTH FACTORS
BY ELECTROPORATION PROMOTES WOUND HEALING AND NEOVASCULARIZATION
Bernadette Ferraro
ABSTRACT

Gene therapy techniques delivering exogenous angiogenic growth factors, such as
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2),
are currently being investigated as potential treatments for ischemia resulting from a
variety of conditions, such as peripheral artery disease (PAD) and chronic wounds.
Despite these intense efforts, a viable clinical option to promote therapeutic
neovascularization remains elusive. Electroporation is a simple in vivo method to deliver
normally impermeable molecules, such as plasmid DNA, to a variety of tissues including
skin and muscle. This study investigated intradermal injection of plasmids encoding
angiogenic growth factors with electroporation as a novel therapeutic approach to
increase perfusion in areas of ischemia. Two common animal models of ischemia were
employed: a skin flap model, used to study wound healing, and a hindlimb ischemia
model, used to investigate potential therapies for PAD. In the skin flap model, delivery
of plasmid VEGF with electroporation significantly increased VEGF expression for 5
days after delivery compared to injection of the plasmid alone. While the increase in
VEGF expression was short-term, it significantly increased expression of the downstream
angiogenic growth factor endothelial nitric oxide synthase, as well as perfusion and
xi

healing in the distal area of the skin flap. To facilitate the translation of electroporation
to the clinic, a novel electrode configuration was previously designed for cutaneous
delivery of plasmids to a large surface area. The design of the Multielectrode Array
allows for delivery to a large surface area without the need to increase the applied
voltage. Conditions for plasmid delivery with this electrode were optimized and it was
then utilized to deliver plasmid FGF-2 (pFGF) to the hindlimb ischemia model. FGF-2
expression, perfusion, and angiogenesis were assessed. FGF-2 expression was
significantly higher for 10 days after treatment with pFGF with electroporation compared
to injection of pFGF alone. This increase in FGF-2 expression induced a significant
increase in perfusion and angiogenesis in the ischemic limb. The research presented here
suggests intradermal injection of plasmids encoding angiogenic factors by electroporation
is a novel potential therapeutic approach to increase perfusion to areas of ischemia and
promote wound healing.

xii

GENERAL INTRODUCTION

Neovascularization

Neovascularization plays a major role in both health and disease. The formation
of new blood vessels occurs during normal physiological processes, such as embryonic
development and wound healing, but excessive neovascularization contributes to the
pathology of several diseases, notably cancer as well as ocular and inflammatory
disorders. Aberrant neovascularization is also associated with many other diseases
including diabetes mellitus, asthma, psoriasis and arthritis. In contrast, insufficient
neovascularization is characteristic of other diseases including ischemic heart and limb
diseases, neurodegeneration and osteoporosis [1]. New vessel growth occurs by three
main mechanisms: angiogenesis, arteriogenesis and vasculogenesis. In embryonic
development, vasculogenesis refers to the formation of the capillaries by the mobilization
of bone marrow-derived endothelial stem cells that will eventually form the vasculature
of the adult [2]. In the adult, vasculogenesis is simply a term for angiogenesis
characterized by intussusception of progenitor cells in and around the new vascular
structures [3]. Angiogenesis refers to the sprouting of new capillary-like structures from
existing vasculature initiated in response to tissue hypoxia [4]. In contrast, arteriogenesis
occurs in response to chronic or acute occlusion of a major artery, such as the coronary or
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femoral artery. In arteriogenesis, preexisting arteriolar connections are recruited to
bypass the site of occlusion in response to an increase in fluid shear stress [5].
It is currently not well understood how the stimulus of increased shear stress is
transmitted from the endothelial cell (EC) membrane to the nucleus, but increases in
fluid shear stress result in the production of the vasodilator nitric oxide (NO) and the
activation of ECs and transcription factors, including early growth response factor-1
(Egr-1) and activator protein-1 (AP-1) [5]. Once activated, transcription factors increase
the expression of chemokines, notably MCP-1, and adhesion molecules, such as
intracellular adhesion molecule-1 (ICAM-1) [2, 6]. The second stage of arteriogenesis is
mediated by an inflammatory response. The presence of MCP-1 and other chemokines
on the cell surface of the activated ECs results in a chemotactic gradient that recruits
circulating monocytes. Adherence of monocytes to the vascular endothelium is enhanced
by the presence of selectins, intracellular adhesion molecules and vascular adhesion
molecules. Monocytes, or after maturation macrophages, then migrate into the deeper
areas of the collateral vessel wall where they induce EC and smooth muscle cell (SMC)
proliferation. This process results in the release of growth factors and cytokines that
promote vascular wall remodeling [3, 5]. In several months the new collateral artery is
almost indistinguishable from a normal artery, except for a slightly higher collagen
content between the smooth muscle layers [7].
The initiation and progression of angiogenesis is mediated through the temporal
and spatial production of multiple growth factors and cytokines. Consistent with hypoxia
being the driving force of angiogenesis, the transcription of multiple genes that play a
role in angiogenesis is induced by hypoxia, primarily through the action of hypoxia2

inducible transcription factors HIF-1β, HIF-1α and HIF-2α. Angiogenesis initiates with a
hypoxia-mediated increase in nitric oxide synthases leading to increased NO production
and subsequently vasodilation [8, 9]. Following vasodilation, vascular permeability
increases in response to VEGF signaling allowing for the extravasation of plasma
proteins that lay down a provisional scaffold for migrating ECs. The destabilization of
mature vessels by matrix metalloproteinases (MMPs) and other proteases then liberates
ECs that migrate to the distal site of neovascularization. The ECs then proliferate to form
an immature vessel lumen which is stabilized by a covering of pericytes and vascular
SMCs recruited to the new vessels by the chemotactic action of PDGF-ββ [9].

VEGF regulation of neovascularization

VEGF is a highly specific mitogen for vascular ECs and exerts its effects mainly
during angiogenesis, not arteriogenesis. VEGF does not naturally associate with or
induce arteriogenesis in vivo because it occurs in a normoxic environment [10]. VEGF165
(referred to as simply VEGF throughout this manuscript) is the predominant isoform of 5
isoforms (VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206) generated by
alternative splicing of the VEGF-A gene. These isoforms differ not only in their
molecular mass but also in their biological properties [11, 12]. VEGF expression levels
are increased in response to hypoxia by both transcriptional mechanisms, through the
actions of HIF-1, and by stabilization of and increased translation of VEGF mRNA [1315]. Several angiogenic growth factors, including epidermal growth factor, PDGF and
FGFs, and inflammatory cytokines, such as interleukin-2, also upregulate VEGF mRNA
[16]. In vitro and in vivo studies have demonstrated that the level of VEGF expression
3

must be finely regulated to induce successful angiogenesis [17-20]. High levels of
constitutive VEGF expression can result in edema [21], formation of hemangiomas and
unstable immature vessels [17-20, 22]. In contrast, low levels or premature cessation of
VEGF expression results in regression of the newly formed vessels [23].
The downstream effects of VEGF are mediated by two tyrosine kinase receptors,
VEGF Receptor 1 (VEGFR1) and VEGF Receptor 2 (VEGFR2). VEGFR1 has a high
affinity for VEGF, however its tyrosine kinase activity is approximately 10-fold weaker
than VEGFR2. VEGF binding to VEGFR1 weakly induces EC proliferation, simulates
the migration of monocytes and induces MMPs and proteases that degrade the ECM
resulting in the release of angiogenic growth factors [16, 24]. It is generally accepted that
VEGFR2 is major mediator of the mitogenic, angiogenic and vessel permeability
enhancing effects of VEGF. VEGF binding of VEGFR2 also induces the
phosphorylation of PI3K to promote EC survival and activates the Raf-MEK-ERK
pathway to increase EC proliferation [16]. VEGF-mediated increases in vascular
permeability are largely due to an upregulation of endothelial nitric oxide synthase
(eNOS) that stimulates the production and release of NO [25-27].

FGF regulation of neovascularization

In comparison to the VEGF family, the FGF family is much more complex
containing 23 known isoforms that share approximately 30–70% homology in their
amino-acid sequences. FGF-1 and FGF-2 differ from other members of the FGF family
in that they lack a signal sequence for extracellular transport, but are instead exported by
an alternative pathway during active angiogenesis [28]. FGF-1 (also known as acidic
4

FGF), FGF-2 (also known as basic FGF) and FGFs 4, 5 and 8 have been shown to play a
role in neovascularization, but much of the in vivo and in vitro research centers on the
actions of FGFs 1 and 2.
After FGF-1 and FGF-2 are exported from ECs they bind FGF receptor 1
(FGFR1) or FGF receptor 2 (FGFR2) to promote both angiogenesis and arteriogenesis by
increasing vascular EC proliferation, migration and degradation of the ECM. Activation
of FGFR1 and FGFR2 by the binding of FGF-1 or FGF-2 increases EC proliferation
through activation of MAPK signaling pathway [29]. In addition to activation of the
MAPK signaling cascade sustained activation of PKC is required for FGF-2 to exert its
full mitogenic effect in ECs [30]. Activation of both the MAPK pathway and PKC are
also required for FGF-1 and FGF-2 mediated cell migration [31]. During arteriogenesis,
the release of FGF-2 from macrophages enhances both EC and SMC proliferation in the
vascular wall [32]. FGF-1 and FGF-2 promote ECM degradation by upregulating the
expression of uPA and the expression of the uPA receptor on the surface of ECs. uPA
converts plasminogen to the serine protease plasmin. Plasmin degrades fibrin, as well as
other ECM proteins, and activates MMPs.

Expression of the uPA receptor on ECs

localizes proteolytic degradation to leading edge of the front of EC migration. While
FGF-1 and FGF-2 initially promote ECM degradation, during the later steps of
neovascularization they promote the formation of the ECM to stabilize the newly formed
vessels [31]. FGF-2 also regulates EC morphogenesis, the reorganization and assembly
of ECs into three-dimensional tubes, by signaling through VEGFR1 [33]. There is a
considerable degree of cross-talk between FGF-2 and VEGF/VEGFRs. Several studies
have shown that FGF-2 may require the activation of VEGF/VEGFRs to promote
5

angiogenesis, and, under some conditions VEGF may also require FGF-2 to exert its
angiogenic effects [34, 35].

Methods of therapeutic gene delivery

Therapeutic delivery of exogenous angiogenic growth factors and cytokines to
increase neovascularization, or therapeutic angiogenesis, has been investigated as a
potential treatment for ischemia-related diseases and to promote wound healing. The
main obstacle for widespread use of gene therapy approaches for the treatment of
diseases in general is the lack of a safe and efficient system for delivery of transgenes.
The simplest gene transfer approach is direct injection of naked plasmid DNA.
This method has had some success, but is limited by low expression levels due to
inefficient uptake of the plasmid by cells [36]. Thus, methods to increase the expression
of plasmids encoding genes of therapeutic interest for the treatment of a particular disease
are actively being explored. In vivo gene therapy approaches can broadly be divided into
two categories, viral and non-viral. Viral approaches utilize a variety of genetically
engineered viral vectors for gene delivery while non-viral approaches focus on the use of
chemical or physical methods to increase the uptake and expression of plasmid DNA.
Direct injection to the target tissue or intravenous administration of recombinant proteins
has also been investigated as a therapeutic approach. Recombinant proteins can also be
topically applied to promote wound healing. The efficacy of recombinant protein
delivery is often hampered by the short-half life, and subsequently low bioavailability, of
many proteins of therapeutic interest [37-41].
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Viral vectors have been employed to deliver genes to provide either transient or
permanent transgene expression. Viral vectors that do not integrate into the host genome,
such as adenoviral and vaccinia vectors, confer transient expression that is relatively
short-term (1 to 2 weeks) compared to expression levels achieved with viral vectors that
do integrate into the host gene. Vectors that do integrate into the host genome, such as
retroviral and adeno-associated viral vectors, confer high levels of permanent transgene
expression [42]. Through 2007, viral vectors have been used in approximately 67% of
gene therapy clinical trials worldwide, with adenoviral (25%) and retroviral (23%)
vectors being the most common [43]. The safety of viral vectors has been questioned as
a result of adverse events in human clinical trials. In clinical trials, adenoviral vectors
have caused severe inflammatory responses, formation of antibodies to the adenoviruses,
transient fever, hepatotoxicity and in rare cases, death [44-46]. The use of retroviral
vectors was questioned after patients developed leukemia in a clinical trial treating
adenosine deaminase deficiency, a fatal autosomal recessive form of severe combined
immunodeficiency (SCID) [47]. The preference of retroviral vectors to integrate into the
genome at transcriptional start sites and introns is the most probable cause of the adverse
events reported in the first SCID trial [48], but the frequency of integration was also
likely to be higher than normal due to a number of secondary risk factors associated with
SCID [49]. In contrast to earlier reports, a more recent SCID gene therapy clinical trial
reported positive results and no adverse effects in patients transfused with autologous
bone marrow cells transduced with a retroviral vector containing the adenosine
deaminase gene [50]. This recent success may lead to renewed interest and more
investigations of therapeutic gene delivery using retroviral vectors.
7

As mentioned above, non-viral approaches for therapeutic gene delivery
encompass chemical or physical methods to increase transfection of plasmid DNA.
Chemical methods for non-viral gene delivery are largely based on the use of positivelycharged cationic liposome complexes. Combining the cationic liposomes with
negatively-charged plasmid DNA facilitates the uptake of the plasmid by the cell
membrane, and subsequently, plasmid internalization. Cationic liposome-mediated gene
transfer is technically simple and can be used for the delivery of a large amount of DNA
by direct injection or intravenous administration, but this approach generally does not
confer high levels of transgene expression [51, 52]. Interestingly, the transfection of
plasmid DNA with cationic liposomes was not enhanced in mouse skin with the addition
of in vivo EP (discussed below) indicating other physical methods of delivery may not be
efficacious for enhancing the effects of these reagents [53].
A variety of physical methods have been explored to increase plasmid gene
transfer including ultrasound, laser, particle bombardment, magnetic fields,
hydrodynamic pressure and in vivo EP. The use of ultrasound, focused lasers, particle
bombardment (also known as the gene gun) and magnetic fields share the common
advantage of being non-invasive approaches, but generally do not confer a substantial
increase in transgene expression compared to direct injection of plasmid DNA alone [54].
Hydrodynamic pressure, rapidly injecting a large volume of plasmid DNA into the tail
vein of rodent models, has been successfully used to transfect hepatocytes throughout the
majority of the liver [55, 56]. This approach has also been successful for gene delivery to
the kidney [57]. While useful for studies in rodent models, however, it is currently not
directly applicable to humans.
8

In vivo electroporation for gene delivery

In vivo EP involves the application of a controlled pulsed external electric field
that slightly surpasses the capacitance of the cell membrane. Application of the electric
pulse transiently increases cell membrane permeability allowing for an increase in the
uptake of plasmid DNA. The first significant demonstrations of successful delivery of
plasmid DNA with in vivo EP were conducted in rat liver [58], murine brain tumors [59]
and murine skeletal muscle [60]. Since these initial experiments, in vivo EP has also
been used for plasmid delivery to a wide variety of tissues including skin [61-77], brain
[78-81], kidney [82] and lung [83-86].
EP delivery of plasmids encoding genes with therapeutic potential to the skin
could potentially be used to treat a variety of diseases. The skin is an attractive target for
delivery of plasmid DNA because it is easily accessible, which allows for enhanced
control over expression levels. If higher expression levels are needed, the area treated or
number of treatments can be increased. Further, plasmid DNA has been successfully
delivered to the skin with in vivo EP for both systemic and tissue-specific expression [6163, 67, 69]. This approach has shown promise in several fields including vaccines [6973] and wound healing [74-77] . A recent publication by Daud et al. [87] reported the
results of the first human trial utilizing in vivo EP for plasmid delivery. The trial
investigated intra-tumoral delivery of a plasmid encoding interleukin-12 (IL-12) with in
vivo EP as a possible therapeutic option for the treatment of metastatic melanoma. The
results of this Phase I trial indicated the potential treatment to be promising as well as
safe, effective, and reproducible. Importantly, intra-tumoral delivery of plasmid IL-12 by
in vivo EP allowed for control of IL-12 expression levels.
9

Previous work in the Heller laboratory led to the development of a novel electrode
configuration, the Four Plate Electrode (4PE), that was optimized for cutaneous plasmid
delivery with EP with minimal tissue damage [68]. As the name suggests, the 4PE is
composed of 4 metal plates that grip the injection site and a nonconductive ‘stopper’
placed in the center of the 4 plates (Figure 1). The use of an
electric field to increase plasmid uptake and expression is more
efficient when the electric field is applied in more than one
direction [88-90]. This approach permeabilizes a greater area of
the cell surface and a larger number of cells in the target tissue
Figure 1. The Four
Plate Electrode
The 4PE in the open
(a) and closed (b)
positions.

[91]. The design of the 4PE allows for the application of 2 sets
of electric pulses, with the second set of pulses rotating 90o
relative to the first set of pulses, without removing the electrode

from the delivery site. Prior to the development of the 4PE, electrically mediated
delivery of plasmids to skin was typically facilitated with a 2-plate caliper electrode. One
drawback to this approach was the requirement of the electrode plates to be manipulated
around the treatment site to administer 2 sets of pulses. Removal and replacement of the
caliper electrode from the delivery site resulted in variation in the distance between the
electrode plates and thus variation in the applied voltage. The nonconductive ‘stopper’
that is placed in the center of the 4 plates of the 4PE ensures a constant distance between
the plates and thus constant voltage across the delivery site.
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Wound Healing

Wound healing is frequently defined as the repair or reconstitution of a defect in
an organ or tissue, commonly the skin. Cutaneous wounds are classified as acute, having
occurred within the past 3 to 4 weeks, and chronic or delayed healing, persisting 6 to 8
weeks or longer [92]. Surgical intervention to facilitate wound healing can be described
as healing by primary intention, delayed primary closure or secondary intention. Primary
intention and delayed primary closure are achieved by suturing or stapling to join the
wound edges, but the latter refers to wounds that are not immediately closed due to
infection or other complications. Secondary intention refers to allowing the wound to
close through the normal healing process.
The process of wound healing occurs in three general overlapping phases: (1) an
inflammatory phase which encompasses coagulation and the initial migration of
inflammatory cells to the wound site (2) a proliferative phase (also known as the
migration phase) involving the migration and proliferation of keratinocytes, fibroblasts
and endothelial cells, leading to re-epithelialization and granulation tissue formation and
(3) an extended remodeling phase which results in a reduction of both cell content and
blood flow in the scar tissue [92, 93]. There is a significant temporal overlap in the
progression through these phases and the later phases of wound repair are critically
dependent on the initial events of the healing process. A deficiency in one or more
essential growth factors or cytokines may result in asynchronous progression through the
phases of wound healing leading to the development of a chronic wound. Several
systemic conditions or diseases, such as malnutrition, immunodeficiency or diabetes
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mellitus, are frequently the underlying cause of the cytokine or growth factor deficiency
and are often associated with impaired healing [94-96].
The inflammatory phase of wound healing begins immediately following injury
with the formation of a fibrin clot to maintain tissue homeostasis and prevent infection.
The fibrin clot consists of platelets embedded in a mesh composed largely of polymerized
fibrin and smaller amounts of fibronectin, vitronectin and thrombospondin [92]. In
addition to serving as a temporary cover of the wound, the fibrin clot also functions as a
scaffold for inflammatory cells. Inflammatory cells are recruited by cytokines and
growth factors released by platelet degranulation and by peptides cleaved from bacterial
proteins [97, 98]. For the first 48 hours following injury, neutrophils are the predominant
inflammatory cell type in the wound. Neutrophils serve several functions in the wound
bed including the removal of dead tissue, prevention of infection and degradation of the
ECM to prepare the wound for the later phases of healing. Additionally, neutrophils are
also a source of proinflammatory cytokines that may provide the earliest signals to
activate keratinocytes, the major constituent of the epidermis, and fibroblasts, which
synthesize the ECM [99]. Between 48 to 72 hours post-injury monocytes / macrophages
replace neutrophils as the predominant inflammatory cell type in the wound area.
Circulating monocytes are recruited to the wounded through the chemotactic effects of
growth factors and cytokines, primarily MCP-1 [100]. Monocytes / macrophages are
essential for effective wound healing. If macrophage infiltration is prevented, wound
healing will be severely impaired [101].
The hypoxic environment of the wound also plays a key role in mediating the
early stages of healing. While prolonged ischemia is deleterious to the healing process
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[96], hypoxia serves a positive role during the early stages of injury. Hypoxia increases
the proliferation of fibroblasts, migration of keratinocytes for re-epithelialization and
promotes early angiogenesis. Moreover, hypoxia induces the transcription of growth
factors, such as VEGF, that are integral to the wound healing process [95, 102].
Due to the temporal overlap of the phases of wound healing, there is some
discrepancy in the time, post-injury, that the proliferative phase begins. In general, the
onset is thought to occur within 2 to 4 days after injury and persist through days 14 to 21
after injury [92, 93]. The proliferative phase is marked by the formation of granulation
tissue and ECM, entrance of macrophages into the wound, angiogenesis and completion
of re-epithelialization. Approximately 4 days after injury, the provisional fibrin clot is
gradually replaced by granulation tissue, which provides a framework for angiogenesis
and cell migration. Granulation tissue is composed of three cell types: ECs, macrophages
and fibroblasts, which drive the production of the ECM. Macrophages in the granulation
tissue continue to secrete growth factors and cytokines to induce fibroblast proliferation,
migration and ECM deposition. Release of angiogenic growth factors, such as VEGF
and FGF-2, by macrophages also facilitates EC morphogenesis and new vessel formation.
Angiogenesis is integral to the wound healing process. If angiogenesis is inhibited, the
healing of a wound will be severely impaired [92, 103]. Another key event that begins
during the proliferative phase is wound contraction. Wound contraction occurs if a
wound was not surgically closed and functions to decrease the wound area. This process
is mediated by fibroblasts that have acquired a contractile phenotype and transformed
into myofibroblasts. Wound contraction begins approximately 5 days after injury and
continues into the onset of the remodeling phase of healing [96].
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The remodeling phase is the longest phase in the wound healing process. It
begins approximately 14 to 21 days after injury and persists for as long as a year,
depending on the size and location of the wound. Currently, remodeling is the least
characterized phase of healing and its regulation is poorly understood. At the onset of the
remodeling phase, new blood vessels that are no longer required to supply nutrients to the
injured tissue regress and re-epithelialization is completed. During the remodeling phase,
the type III collagen that was synthesized by fibroblasts in the granulation tissue is slowly
degraded by the action of MMPs and replaced by type I collagen. The replacement of
type III collagen by the stronger type I collagen, coupled with an increase in collagen
cross-linking, slowly improves the tensile strength of the wound [92, 93, 96]. At the
beginning of the remodeling phase, the strength of the wound is approximately 20% of
intact skin, but it continues to increase during the phase to reach a maximum of 80% at 1
year following injury [104].

Skin flaps

Skin flaps are frequently used in plastic and reconstructive operations to repair
large skin defects and deep wounds formed from injuries, operations, ulcerations or
congenital defects. In skin flap surgery, a piece of full thickness skin is transferred to the
affected area while remaining attached to the donor site by a vascular pedicle. Because
skin flaps receive their blood supply from the donor site they are preferable over skin
grafts to cover recipient beds of poor vascularity, such as areas of exposed bone and
tendons [105]. Moreover, skin flaps often provide better cosmesis when repairing
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delicate areas, such as facial structures, and are less prone to wound contraction than skin
grafts [106, 107].
Skin flaps are grouped into two general categories, axial and random. The pedicle
of axial pattern skin flaps is based on a defined vascular territory and the blood is
supplied through the vascular pedicle by a direct subcutaneous artery. In contrast, the
pedicle of random skin flaps (RSFs) is based on random, non-dominant vessels and the
vascular pedicle contains only small musculocutaneous or septocutaneous perforators
[108]. In both axial and RSFs, insufficient arterial supply and inadequate venous
drainage can lead to ischemia and necrosis of the distal portion of the skin flap. RSFs are
considered more at risk for necrosis than axial skin flaps, due to the low level of blood
supplied to the flap by the small vessels in the pedicle, and the instability of RSFs further
increases when the length to pedicle width ratio exceeds 2.5 to 1 [109]. The tendency of
the distal region of skin flaps to suffer severe ischemia and necrosis remains a significant
issue in the clinic, but has also provides researchers with a valuable tool to study wound
healing in animal models in the laboratory [110].
Currently, the use of the technique of surgical delay is the standard method used
clinically to increase skin flap survival. Surgical delay consists of partially elevating and
undermining the skin flap 7 to 14 days prior to full elevation and inset. Investigations of
the molecular mechanisms by which the delay procedure increases skin flap viability
have found that the procedure increases the expression of both FGF-2 and VEGF, but not
TGF-β or PDGF [111-113]. Gene therapy techniques delivering exogenous growth
factors, such as VEGF and FGF-2, may therefore mimic the endogenous response to
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surgical delay and are currently being investigated to increase skin flap perfusion and
healing.

Therapeutic angiogenesis to promote wound healing

Preclinical studies have shown that therapeutic angiogenesis is a promising option
for increasing wound healing, but as of 2007 there were only a small number of clinical
trials investigating gene transfer approaches targeting wound healing [41, 51]. A
multitude of growth factors have been investigated to promote all phases of wound
healing in both skin flap and incisional wound models [51, 98]. For example, therapeutic
delivery of members of the FGF family has shown promise for increasing wound healing.
In vivo EP delivery of a plasmid encoding KGF-1, (also known as FGF-7) increased
healing in both a diabetic mouse [76] and septic rat model [77]. Also, liposome-mediated
delivery of plasmid KGF-1, in combination with a plasmid encoding IGF-1, accelerated
re-epithelialization and increased expression of VEGF in an acute wound model [114].
Further, transfer of FGF-2 by recombinant protein injection [115] or plasmid with in vivo
EP increased skin flap survival [116].
PDGF and VEGF have been the most intensely studied growth factors for
promoting therapeutic angiogenesis to increase wound healing. In preclinical studies,
delivery of exogenous PDGF by viral-mediated transfer [117-119] and by direct injection
[120] or liposome-mediated [121] delivery of a plasmid encoding PDGF successfully
increased wound healing. In addition, a topical gel containing recombinant PDGF,
Regranex (Ortho-McNeil), is currently prescribed for the treatment of diabetic
neuropathic foot ulcers [39]. In several multicenter trials, daily application of Regranex
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only modestly increased ulcer closure. Specifically, ulcer closure ranged from 25% to
36% with the placebo gel and from 36% to 50% with Regranex [122]. Topical
application of recombinant VEGF protein has also been investigated as potential
treatment to increase healing of diabetic neuropathic foot ulcers. In a Phase I clinical
trial, application of a cream containing recombinant VEGF protein every 2 days for 6
weeks showed a positive, but not statistically significant, trend in ulcer healing [123]. In
contrast, preclinical studies have shown direct injection or systemic delivery of
recombinant VEGF protein improves skin flap survival [124-127]. One study
demonstrated that intravenous delivery of VEGF protein was more effective than
localized injection [124], but this approach raises the concern for pathological
angiogenesis that may result from systemic VEGF expression [17-20]. Also in
preclinical models, viral-mediated [128-131] transfer of VEGF and direct injection [132134], liposome-mediated [120] or transfer in a fibrin matrix [135, 136] of plasmid VEGF
have all increased skin flap survival. Nonetheless, non-protein methods for gene transfer
of PDGF or VEGF have yet to be explored as a method to increase healing in clinical
trials.
Peripheral Artery Disease

Peripheral artery disease (PAD), commonly resulting from atherosclerosis, is one
of the leading causes of morbidity and mortality in the western world [137, 138]. The
primary pathophysiology of PAD is a reduction in blood flow to the lower extremities
caused by stenosis or occlusion of a collateral artery. The reduction in blood flow
generally results in one of two clinical presentations: intermittent claudication (IC) or
critical limb ischemia (CLI). IC is the most common presentation of PAD and is
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characterized by muscular leg discomfort induced by exercise that is relieved by rest.
Patients with IC are limited in walking speed and distance, and in other measures of
quality-of-life [139]. CLI, a less common but more severe presentation of PAD, results
from insufficient blood flow to the affected limb even at rest. The decrease in blood flow
to the limb with CLI is so severe that limb loss is likely without therapeutic
revascularization. There are a myriad of symptoms associated with CLI, including: rest
pain in the extremity, metatarsalgia (pain and inflammation of the metatarsal region of
the foot), ulcers or wounds that fail to heal, and gangrene [140].
Current treatment options for PAD include risk factor reduction, physical therapy
and training, and pharmacological treatment of the underlying atherosclerosis. Also, in
patients with severe IC or CLI, interventional (catheter based) or open surgical
procedures may be used to revascularize the ischemic limb. A pharmacotherapy to
increase perfusion to the effected limb is not available, and treatments targeting the
underlying atherosclerosis are largely ineffective.

Cilostazol, a reversible

phosphodiesterase-3 inhibitor, has shown some clinical benefit for treatment of IC, but
cannot be used in patients with any degree of heart failure [141]. Pentoxifylline, a
pharmacological treatment that decreases blood viscosity and thereby increases
circulation in the limb, is widely prescribed in the United States for the treatment of IC
but has little or no clinical benefit [141, 142]. As mentioned above, revascularization of
the lower extremity for patients with severe IC or CLI can be accomplished by
interventional catheter-based techniques as well as open surgical procedures. However,
direct revascularization is often impossible due to the anatomic extent of PAD and is also
limited by associated co-morbidities, such as diabetes, coronary artery disease or stroke,
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requiring a majority of patients to undergo limb amputation [138, 143-145]. The lack of
an effective pharmacological treatment and the limits of interventional and surgical
procedures have spurred an intense investigation of alternative approaches, such as
therapeutic angiogenesis, for the treatment of PAD.

Preclinical models of limb ischemia

Animal models of hindlimb ischemia are the standard preclinical model for
evaluating potential therapies for limb ischemia. The first characterization of an animal
model of hindlimb ischemia was in the 1950s with studies in the rabbit [146]. Since this
initial work, experimental hindlimb ischemia models have been developed in both large
and small animals. In general, large animal models, such as swine and canine, are
advantageous because the limb vessels and associated branches are easily identifiable
while small animal models, such as mouse and rat, are advantageous because of their low
cost and the availability of transgenic lines.
The design of preclinical limb ischemia models varies, and the level of ischemia
achieved by each design depends greatly on the species and even the strain of animal
[147]. The most common approaches to induce hindlimb ischemia are the tourniquet
technique, simple ligation of the common femoral or common iliac arteries, and ligation
with excision of these arteries and their distal branches. The tourniquet technique is a
non-invasive approach that has been used in both large and small animal models to
interrupt all arterial and venous blood flow to the limb, including blood flow from
potential collateral vessels [148]. This approach results in a rapid onset of severe muscle
necrosis and is more appropriate for studying acute ischemic injury than the chronic
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occlusive disease characteristic of PAD. The level and duration of ischemia achieved by
ligation of the common femoral or common iliac artery depends greatly on the level of
collateral blood flow in the species. In general, this technique fails to produce chronic
ischemia at rest, as seen in patients with CLI, but in some species and transgenic models
it does result in a reduction in blood flow with exercise, characteristic of patients with IC
[147, 149, 150]. In animals with an extensive network of collateral vessels, such as the
rat [151], ligation of the common femoral [152] or common iliac artery [153] only
transiently decreases blood flow to the limb. However, a study by Angersbach et al.
[154] suggested that prolonged ligation of the femoral artery in the rat will eventually
result in similar symptoms to IC. In comparison to simple ligation, ligation and excision
of the most distal point of the external iliac or common femoral and associated distal
branches reduces blood flow to the limb at rest, even in model systems with extensive
collateral networks such as the rat [147, 155-157]. Thus, the ligation and excision
method is considered an appropriate model to study potential therapies for CLI [147, 155157].
Although there are differences in the methodology and resulting ischemia in the
above mentioned preclinical models, all of these models are associated with some degree
of perfusion recovery even without therapeutic intervention. Thus, the timing of delivery
of potential therapeutics and assessment of limb perfusion is critical. Interventions
delivered at the time of surgery, or shortly thereafter, will effectively measure the ability
of the intervention to improve limb perfusion. If the intervention is delivered at later time
points, usually no later than postoperative day (POD) 7, the ability to detect the
effectiveness of the intervention will be hampered because perfusion in the ischemic limb
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will be naturally nearing that found in the non-ischemic limb, which is often used as a
control [147]. There are multiple methods to determine the effect of a potential treatment
on limb blood flow in preclinical models. Histological assessment of capillary density
alone is not an accurate measure of perfusion and should be supplemented by a method
that detects limb blood flow directly such as calf blood pressure ratio, laser Doppler
perfusion imaging (LDPI) or magnetic resonance imaging.

Therapeutic angiogenesis for the treatment of limb ischemia

Gene therapy techniques delivering angiogenic growth factors are emerging as
promising options for the treatment of IC and CLI in patients when direct
revascularization is not possible. A large number of angiogenic growth factors and
cytokines have been explored as therapeutic candidates in both preclinical models and
clinical trials [158]. Of these, FGF-1, FGF-2 and members of the VEGF family have
been the most actively investigated, but several other growth factors have successfully
promoted therapeutic angiogenesis in preclinical models including HIF-1α [159, 160],
MCP-1 [161, 162] and eNOS [163, 164]. Hepatocyte growth factor (HGF) has also
shown promise for therapeutic angiogenesis in both preclinical models [165, 166] and
Phase I clinical trial as a treatment for CLI [167]. In clinical trials, several end points are
measured to determine the efficacy of the treatment. In patients with IC, leg pain induced
by exercise is the main clinical manifestation. Thus, quality-of-life questionnaires, peak
walking time, and measurements of limb blood flow, such as ankle brachial index (ABI)
or LDPI, are considered appropriate clinical trial end points. Because the clinical
manifestations and prognosis of limb ischemia are more severe with CLI, trials
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investigating therapeutic angiogensis for the treatment of CLI often include additional
end points, such as the size and healing of ulcers and, when appropriate, loss of tissue
[140].
There have been multiple Phase I and II clinical trials investigating VEGF as a
therapeutic agent for the treatment of PAD. Phase I clinical trials investigating
intramuscular injection [168-170] and intra-arterial infusion [171] of plasmid VEGF165
showed the treatment increased angiographic score, ABI, and ulcer healing and decreased
the incidence of limb loss in patients with CLI. In a Phase II trial conducted in patients
with both CLI and diabetes mellitus, intramuscular injection of plasmid VEGF165
increased ABI and ulcer healing [172]. Also, in a Phase II trial intra-arterial
administration of adenoviral-VEGF165 in combination with plasmid VEGF165 increased
angiographic score in patients with CLI [173]. Clinical trials have also been conducted
with adenoviral VEGF121. In Phase I trials, intramuscular injection of adenoviral
VEGF121 increased peak walking time [174], but when moved into Phase II trials there
was not a significant improvement in the end points measured (quality-of-life and peak
walking time) [175].
Of the FGF family members FGF-1 and FGF-2 have been the most intensely
studied and most frequently utilized in emerging therapeutic angiogenesis approaches. In
a Phase II clinical trial intramuscular injection of plasmid FGF-1 was well tolerated and
decreased the incidence of limb amputation in patients with CLI [176]. Patients for a
Phase III trial are currently being recruited to continue the study of intramuscular
injection of plasmid FGF-1 for the treatment of PAD [177]. There have been several
clinical trials investigating the use of recombinant FGF-2 protein to promote therapeutic
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angiogenesis in patients with PAD. In a Phase I trial, intra-arterial delivery of
recombinant FGF-2 significantly increased calf blood flow [178]. In another Phase I / II
trial, recombinant FGF-2 suspended in a biodegradable gelatin hydrogel to promote
sustained release was injected into the gastrocnemius muscle in patients with CLI. In
comparison to baseline, the patients in this study showed significant improvements in
peak walking time, limb perfusion and healing of foot ulcers [179]. In the Phase II
Therapeutic Angiogenesis with FGF-2 (TRAFFIC) trial, intra-arterial injection of
recombinant FGF-2 protein significantly improved peak walking time and ABI, but no
differences were seen in claudication onset time or quality-of-life measurements [180].
Non-protein methods delivering FGF-2 to promote therapeutic angiogenesis have yet to
be explored in clinical trials. Given the success intramuscular injection of plasmid FGF-1
in CLI patients, it would be of interest to explore other gene therapy approaches to
deliver FGF-2 in clinical trials.
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CENTRAL HYPOTHESIS

The end goal of therapeutic angiogenesis is to increase the amount of nutrients
supplied to and the rate of waste product removal from ischemic tissue by increasing
vasodilation, vascular permeability, neovascualarization and, subsequently, blood flow.
As a whole, this research explored the hypothesis that intradermal injection of plasmids
encoding angiogenic growth factors followed by non-invasive in vivo EP is a feasible
approach for promoting therapeutic angiogenesis in ischemic tissue to increase perfusion.
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INTRADERMAL DELIVERY OF PLASMID VEGF165 BY ELECTROPORATION PROMOTES
WOUND HEALING

Introduction

In addition to direct injection of plasmid DNA, the most prevalent methods of
therapeutic delivery of VEGF to skin flaps documented in the literature are adenoviralmediated gene transfer and recombinant protein injection. These methods have shown
promise for increasing skin flap healing [124-134, 181] but have draw backs (see General
Introduction, Methods of therapeutic gene delivery). Moreover, in comparison to nonviral approaches, transgene expression with adenoviral-mediated delivery persists longer
increasing the potential for the occurrence of the adverse side effects associated with
continuous unregulated VEGF expression [17-20]. Thus, the development of a gene
transfer approach that allows for tight control over expression level and duration would
be advantageous for VEGF-mediated therapeutic angiogenesis. The research presented

Figure 2. The random skin flap model
Left Approximate placement of the RSF. Center Location of the distal
area monitored for perfusion and healing. Right approximate location
of the treatment sites
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in this Chapter investigated intradermal injection of pVEGF followed by in vivo EP,
using the 4PE, as potential therapy to increase wound healing. This strategy was explored
using a modified McFarlane [182, 183] 8 cm x 3 cm RSF model (Figure 2). Specifically,
pVEGFE+ or control treatments were delivered at 4 sites to the RSF on POD 2. VEGF
expression kinetics and the ability of the treatment to increase an endogenous angiogenic
response, perfusion and healing were evaluated.

Results

In vitro plasmid VEGF expression

The ability of pVEGF to increase VEGF expression was tested in vitro prior to
use in vivo. The promoter and coding region of VEGF was removed from pBLASTVEGF and cloned into the backbone of pVAX1 to allow for more efficient preparation of
large quantities of the plasmid. The level of VEGF expression with pVEGF was
equivalent to that with pBLAST-VEGF in both the cell lysate and cell culture supernatant
48 hours after lipid-mediated transfection (Figure 3).
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Figure 3. In vitro plasmid VEGF expression
Average VEGF expression ± SD was determined by ELISA 48 hours after lipidmediated transfection of B16F10 cells with pVEGF or pBLAST-VEGF. For the mock
transfection, cells were treated with the transfection reagent without plasmid DNA.
n=3 for all groups.

VEGF expression kinetics in the gastrocnemius muscle

Plasmids encoding a wide variety of genes with therapeutic potential, including
VEGF, have been successfully delivered to skeletal muscle by intramuscular injection
and in vivo EP [54, 184] resulting in increased transgene expression compared to
injection of the plasmid alone. After determining pVEGF increases VEGF expression in
vitro, in vivo expression was confirmed by delivering pVEGFE+ and pVEGFE- to the rat
gastrocnemius muscle. On days 2, 5 and 7 after pVEGF delivery, muscle was excised
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from the delivery sites and assayed for VEGF expression using an ELISA that
specifically detects human VEGF165. Compared to pVEGFE-, VEGF expression was
significantly greater with pVEGFE+ for 5 days after delivery (Figure 4).

Figure 4. pVEGFE+ increases VEGF expression in the gastrocnemius
muscle
pVEGFE+ increased VEGF expression in gastrocnemius muscle compared to
pVEGFE-. Day 2 and day 7: n=6 per group, Day 5: pVEGFE- n=5; pVEGFE+
n=4. * p< 0.05.

VEGF expression kinetics in the random skin flap

Because pVEGFE+ successfully increased VEGF expression in gastrocnemius
muscle it was then investigated whether the same increase could be achieved with
pVEGFE+ in the skin of the RSF model. Skin flaps were treated on POD 2. On PODs 4,
7, 10 and 14, skin samples from the treatment sites were excised and assayed for VEGF
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expression using an ELISA that specifically detects human VEGF165. Necrosis prevented
some sites from being harvested, especially in the pVEGFE- group at later time points.
On both PODs 4 and 7, VEGF expression was significantly higher in the pVEGFE+
treatment group compared to the pVEGFE- treatment group (p< 0.05, both time points)
(Figure 5). VEGF expression was determined for each treatment group in the proximal
area, closest to the RSF pedicle, and distal area, farthest from the RSF pedicle.
Interestingly, on POD 4, VEGF expression was significantly higher in the distal area of
the RSF, compared to the proximal area, for the pVEGFE+ treatment group (p<0.05).
There was a 2-fold increase in VEGF expression in the distal area, compared to the
proximal area, with pVEGFE-, but this increase was not statistical significant (p= 0.157).
The level of VEGF expression achieved with pVEGFE+ in the distal area of the RSF was
similar to the level and duration observed in the gastrocnemius (Figures 4 and 5).
Compared to POD 4, there was an overall significant decrease in VEGF expression on
POD 7 (p< 0.05, both treatment groups in both the proximal and distal areas) but levels
were still significantly higher with pVEGFE+ compared to pVEGFE- in each area (p<
0.05). At POD 10, there was not a significant increase in VEGF expression with
pVEGFE+ in either the proximal or distal area of the RSF, and by POD 14 only
background levels of VEGF were detected for both pVEGFE+ and pVEGFE-. VEGF
expression was not detected when the vector backbone lacking the VEGF cDNA insert
was delivered to the RSF with EP (pVAXE+) or in the skin of untreated controls (P-E-).
Also, VEGF expression was not detected in serum samples at any time point during the
study (data not shown) indicating pVEGFE+ only increases VEGF expression locally,
not systemically.
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Figure 5. VEGF expression kinetics in the random skin flap
On PODs 4 and 7 VEGF expression was significantly greater with pVEGFE+ than pVEGFE- in
the RSF. VEGF expression was further increased in the distal region of the RSF. pVEGFE-:
POD 4 proximal n=8, distal n=6; POD 7 proximal n=3, distal n=4; POD 10 proximal n=3,
distal n=2; and POD 14 proximal and distal n=2. pVEGFE+: POD 4 proximal n=4, distal n=7;
POD 7 proximal n=7, distal n=6; POD 10 proximal n=3, distal n=4; and POD 14 both proximal
and distal n=3. For groups with n≤3 the mean ± SD is reported. For groups with n >3 the mean
± SEM is reported. * p< 0.05.
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Delivery of plasmid VEGF with electroporation increases eNOS expression

Both in vitro and in vivo studies [26, 185] have shown increases in VEGF can
increase levels of eNOS. To determine if pVEGFE+ and pVEGFE- increased eNOS in
the RSF, skin samples from the distal area of the RSF were assayed for eNOS by ELISA
at both PODs 4 and 7. On POD 4 eNOS was significantly higher following pVEGFE+
treatment compared to pVEGFE- treatment (p< 0.05), but by POD 7 eNOS levels were
similar in the pVEGFE+ and pVEGFE- treatment groups (Figure 6). The application of
an electric field to tissues alone can transiently induce expression of some genes [186188] but pVAXE+ did not increase eNOS in the RSF model (p< 0.01).

Figure 6. pVEGFE+ increases eNOS expression
pVEGFE+ significantly increased eNOS expression in the distal area of the RSF on
POD 4. n=7 per group per time point. * p< 0.05 compared to pVEGFE-. ‡ p< 0.01
compared to pVAXE+.
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Effect of plasmid VEGF with electroporation on distal skin flap blood flow

Because RSF survival shows little change after POD 15 [182] skin flap perfusion
and healing were monitored through POD 14. pVEGFE+ resulted in the highest level of
VEGF expression in the distal area of RSFs, which is more at risk for ischemia and
necrosis since it is farthest from the vascular pedicle. Thus, it was determined if
pVEGFE+ treatment increased perfusion more than control treatments in the distal area
of the RSF, corresponding to approximately 25% of the total RSF area. LDPI was used
to measure perfusion preoperatively (baseline), immediately postoperatively, and on
PODs 2, 4, 7, 10, and 14. A sharp decrease in distal perfusion was observed immediately
postoperatively through POD 4 indicating the RSF was effectively rendered ischemic.
Perfusion for each treatment group is reported as the percent recovery of baseline (Figure
7a) and postoperative perfusion (Figure 7b). At PODs 10 and 14 perfusion was
significantly different between all treatment groups for both recovery of baseline and
postoperative perfusion (p< 0.01). Perfusion in the pVEGFE+ treatment group was
significantly greater than all controls on both PODs 10 and 14 for both recovery of
baseline (p< 0.01) and postoperative (p< 0.05) perfusion.
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a

b

Figure 7. pVEGFE+ increases distal skin flap blood flow
Perfusion was measured in the distal region of the RSF by LDPI at the indicated time
points. pVEGFE+ significantly increased recovery of baseline (a) and postoperative
(b) perfusion on PODs 10 and 14 compared to all controls. n=7 per group, per time
point. ** p< 0.01, *p< 0.05 compared to all controls.
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Plasmid VEGF with electroporation promotes distal skin flap healing

Visual assessment of RSF viability over the time course of the study showed a
clear decrease in distal necrosis in the pVEGFE+ treatment group compared to control
groups (Figure 8, top panel). The surviving region of the distal area of the RSFs was
quantitated on PODs 7 and 14 (Figure 8, bottom panel). To quantitate the percent
survival of the distal area, the area of skin with normal texture and color was expressed as
a percent of the total distal area. Non-surviving areas were defined as dark, rigid necrotic
skin or scabbed necrotic lesions and surviving areas were defined as skin normal in
texture and color. The pVEGFE+ treatment increased the percent of distal RSF survival
on POD 7 (89.4 ± 4.3) (p< 0.05) compared to pVEGFE- (56.6 ± 10.6), pVAXE+ (59.3 ±
9.8) and P-E- (60.2 ± 9.6). The surviving area in all treatment groups increased
approximately 5% to 10% on POD 14, but healing was still greater and more consistent
in the pVEGFE+ group (95.2 ± 2.2) (p< 0.01) compared to pVEGFE- (65.6 ± 9.3),
pVAXE+ (70.6 ± 7.4) and P-E- (73.5 ± 4.1). Adverse side-effects associated with
increased VEGF expression levels, such as edema, [17-20] were not observed by gross
visual assessment in any of the treatment groups. The mean percent survival of the
pVEGFE- group on POD 7 in this study is similar to previously reported values
delivering a plasmid encoding VEGF to a similar RSF model [120, 134]. On POD 14,
skin samples were excised 2-cm from the distal end of the RSFs for histological analysis
by Hematoxylin-Eosin (H&E) staining (Figure 9). If the skin was necrotic at 2-cm from
the distal end, samples were excised near the edge of the surviving border. Skin from the
pVEGFE+ treatment group appeared healthy (Figure 9, a-b) while skin from the
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pVEGFE- treatment group showed evidence of acute inflammation, necrosis and
myonecrosis (Figure 9, c-f).

Figure 8. pVEGFE+ increases distal skin flap healing
(Top) Representative images of RSFs from each treatment group over the time course
of the study. (Bottom) Quantification of distal survival on PODs 7 and 14. n=7 per
group, per time point. ** p< 0.01, * p< 0.05 compared to all controls.
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Figure 9. pVEGFE+ decreases inflammation and myonecrosis
Representative images of skin excised 2-cm from the distal end of RSFs on POD 14 and
stained with H&E from the pVEGFE+ (panels a and b) and pVEGFE- (panels c through f)
treatment groups. Open arrows indicate areas of epidermal lifting characteristic of
necrosis with pVEGFE- (panels c and d) compared to a normal epidermis with pVEGFE+
(panels a and b). Panel f, solid arrow indicates an example of an area of myonecrosis of
the panniculus carnosus muscle observed with pVEGFE-. Open circles (panels d, e and f)
indicate areas of inflammation characterized by the dark staining of numerous
inflammatory cells. Inflammatory infiltrate was not observed with pVEGFE+ (panels a
and b).
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Preliminary studies were completed to explore if alterative treatment time points
would increase RSF healing more than pVEGFE+ treatment on POD 2. It was first
confirmed that pVEGFE+ and pVEGFE- increased VEGF expression when delivered to
the RSF on POD 0 (Figure 10a). While immediate postoperative delivery of pVEGFE+
increased VEGF expression on POD 2, compared to pVEGFE-, the increase was not as
robust as on POD 4 when treating on POD 2 (Figures 5 and 10a). It is possible the lower
level of VEGF expression when treating on POD 0 was due to the need for the tissue to
recover prior to treatment. Also, because VEGF primarily mediates the proliferative
phase of wound healing [189], high levels of VEGF expression during the inflammatory
phase may have been recognized as deleterious to the endogenous wound healing
process. Thus, treatment on POD 0 may have resulted in the exogenous VEGF mRNA or
protein being targeted for degradation. Because of the exploratory nature of these
experiments, the use of experimental animals was minimized. Thus, the small number of
treatment sites assayed resulted in a large variation in VEGF expression (Figure 10a).
RSF healing was also evaluated for the alternative treatment time points (Figure 10b).
RSFs treated with pVEGFE- on both PODs 0 and 2 showed the largest increase in
healing of the alternative treatment time points, but healing with pVEGFE+ treatment on
POD 2 was still greater. Interestingly, RSF healing was much lower with pVEGFE+
treatment on both PODs 0 and 2 compared to treatment on POD 2 alone. This may be
because excessively high levels of VEGF expression can have negative effects on the
process of angiogenesis [17-22].
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b

Figure 10. pVEGFE+ treatment on POD 2 increases healing more than
treatment at POD 0 or multiple time points.
(a) pVEGFE+ treatment on POD 0 increases VEGF expression on POD 2. n=2 per group
for both proximal and distal areas. Mean ± SD is reported (b) Quantification of distal RSF
survival on PODs 7 and 14 when treating on POD 0, POD 2 or both POD 0 and 2.
Treatment on POD 0 and POD 0 and 2 n=2 per group. Treatment on POD 2 n= 7 per
group.
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Discussion

The data presented in this chapter demonstrate a novel therapeutic approach to
increase VEGF expression, induce an endogenous angiogenic response, and increase
perfusion and healing of the distal area of RSFs. pVEGFE+ is an attractive alternative to
viral and recombinant protein gene transfer approaches to promote healing because it
allows for the control of localized expression levels and duration. This approach also
circumvents the adverse side-effects and practicality issues associated with viralmediated and recombinant protein approaches. Previous gene therapy studies delivered
VEGF to skin flaps either preoperatively or intraoperatively [120, 124-133, 135, 136].
This study was the first to deliver pVEGF on the second POD. VEGF modulates the
proliferative phase of wound healing that begins 2 to 4 days after the initial injury [189].
By administering pVEGFE+ on POD 2, VEGF expression was timed to peak during the
beginning of the proliferative phase of healing. Preliminary studies treating the RSFs on
POD 0, and on both POD 0 and 2 suggested that pVEGFE+ treatment on POD 2
increases healing more than treatment at these alternative time points (Figure 10b). Also,
by administering treatment on POD 2, when the distal area of the skin flap is most
hypoxic [190], it was determined that electrically-mediated delivery of plasmid DNA to a
large area of ischemic skin is in fact possible.
These results demonstrate that pVEGFE+ significantly increased VEGF
expression, compared to pVEGFE-, and that VEGF expression further increased with
distance from the vascular pedicle. Also, in the distal area of the RSF, pVEGFE+
resulted in similar levels of VEGF expression as delivery to the gastrocnemius muscle
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(Figures 4 and 5). Higher VEGF expression in the distal area of the RSF, compared to
proximal region, could be due to hypoxia-induced stabilization of the VEGF mRNA or
increased translation [191]. The current known mechanisms to increase VEGF mRNA
stability and translation involve genetic regions not contained within the plasmid used in
this study. It is possible other unknown mechanisms could enhance VEGF levels and
may be responsible for the increase in VEGF expression in the distal area, compared to
the less hypoxic proximal region. Importantly, VEGF expression was transient and not
detected systemically, indicating that the increase was localized to the delivery area.
Moreover, pVEGFE+ confers a short-term localized increase in VEGF expression
thereby decreasing the possibility of the occurrence of the adverse side-effects that are
associated with long-term high levels of VEGF expression [17-22].
The increase in eNOS expression after the pVEGFE+ and pVEGFE- treatments
indicates that the observed increase in exogenous VEGF successfully stimulated an
endogenous angiogenic response. pVEGFE+ induces an earlier and more robust increase
in eNOS expression compared to pVEGFE- (Figure 6). These results are consistent with
reports that in vitro VEGF-induced upregulation of eNOS is time and dose dependent
[192] and with a study by Huang et al. [193] that demonstrated adenoviral delivery of
VEGF165 to RSFs increased eNOS. Relative to pVEGFE-, there was a 2.2-fold increase
in eNOS protein with pVEGFE+ in the distal area of the RSF on the fourth POD that was
mediated by a 6.6-fold increase in VEGF protein (Figures 5 and 6). Significant progress
has been made elucidating the mechanisms underlying VEGF-mediated increases in
eNOS, but many aspects of the complete mechanism remain unclear despite the well
established role of this pathway in wound healing and angiogenesis [163, 193, 194]. In
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vitro [26, 192] studies utilizing the optimal VEGF dosage, and in vivo [193] studies,
have shown that VEGF-mediated increases in eNOS protein levels are typically not
greater than 2- to 5-fold over background levels. In the work presented here, eNOS
levels with pVEGFE+ remain similar from POD 4 to POD 7, but increase with pVEGFEover this time period, suggesting that maximal level of eNOS has been reached in the
pVEGFE+ group on POD 4. The small increase in eNOS levels, relative to VEGF levels,
may be due to inhibition of eNOS production by high levels of NO [195]. Also, the
persistence of eNOS expression in the pVEGFE+ and pVEGFE- treatment groups at
POD 7, despite a decrease in VEGF expression, may be the result of a VEGF-mediated
increase in eNOS mRNA stability [26]. eNOS mRNA has a normal half-life of 48 hours
[196] and further extending the half-life would allow for the increase in eNOS protein to
persist despite a decrease in VEGF levels.
The early increase in eNOS observed with pVEGFE+ could contribute to the
increased perfusion and healing observed at the later time points. eNOS production of
NO is important in the early stages of skin flap healing [197] and contributes to
maintaining peripheral skin flap circulation [198]. Another possible mechanism for the
increased perfusion and healing of the RSF after treatment with pVEGFE+ is increased
neovascularization. There was not a significant increase in vessel density (data not
shown) in skin samples harvested 2-cm from the distal end of the RSFs on POD 14.
Other studies delivering exogenous VEGF to wound healing models have reported the
same phenomenon of increased healing without an associated increase in vessel density
[127, 133] while other studies do not discuss changes in capillary density. To prevent
ischemic necrosis there must be adequate perfusion pressure to the distal region of the
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skin flap [199]. In this study, increased eNOS, and the subsequent increase in
vasodilation, could be the primary mechanism of the pVEGFE+-mediated increase in
perfusion and healing, but determination of the exact mechanism will require further
studies.
In summary, the pVEGFE+ treatment significantly increased VEGF expression
for 5 days after treatment (through POD 7) and this short-term increase was sufficient to
significantly increase eNOS, compared to pVEGFE- treatment, 2 days after treatment.
Further, pVEGFE+ significantly increased recovery of baseline and postoperative
perfusion and as well as healing compared to all control treatment groups. Thus,
electrically-mediated intradermal delivery of pVEGF is a potential non-invasive
therapeutic approach to increase perfusion and wound healing.

Future directions

To move this approach forward into a clinical setting, the efficacy of pVEGFE+
to increase perfusion and healing of RSFs should next be examined in a large animal
model. Porcine skin physiologically resembles that of human skin. Also, direct injection
of plasmid DNA in porcine skin results in a similar expression pattern as in human skin,
suggesting the swine as an appropriate large animal model for future work [200]. Also,
because wound healing is impaired in patients with diabetes mellitus [92, 95], it would be
interesting to explore if pVEGFE+ increases the healing of RSFs in a diabetic model.
Diabetes has been successfully induced in both the rat [201] and swine [202] with
streptozotocin. Also, transgenic rat models of diabetes are available that could be used
for these future experiments [203, 204].
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Experiments investigating the mechanism by which pVEGFE+ significantly
increases VEGF expression in the distal area, compared to the proximal area, of the RSF
could elucidate a novel mechanism of VEGF mRNA stability. The ELISA used in these
studies specifically detects human VEGF165 and because only background levels of
VEGF were detected with P-E- and pVAXE+, it is unlikely that the increase in VEGF in
the distal area of the RSF is due to non-specific detection of endogenous VEGF. The
expression of endogenous VEGF is increased and attenuated during hypoxia by both
transcriptional regulation and mRNA stabilization. HIF-1 increases VEGF transcription
through binding the hypoxia response element in the endogenous VEGF promoter and
VEGF mRNA is stabilized in 5’ and 3’ untranslated regions of the endogenous mRNA
[13-15]. Neither of these genetic regions is present in pVEGF suggesting the increase in
VEGF expression occurs through an unknown mechanism. Several genes, such as c-fos,
c-myc and β-tubulin, contain RNA regulatory elements within their coding regions [205]
and it is possible the increase in VEGF expression in the distal area of the RSF occurs
through a similar mechanism. Endogenous VEGF is increased during hypoxia by
transcriptional mechanisms, but it has been shown that the increase in VEGF protein
occurs mainly through an increase in mRNA stability [13]. In vitro experiments could
be used to determine if the increase in VEGF with pVEGFE+ in the distal area of the
RSF results from increased mRNA stabilization through a regulatory region in the coding
sequence. To evaluate this hypothesis, assays similar to those reported by Shima, et al.
[13] could be used. Briefly, pVEGF would be transfected into a non-human cell line, in
order to distinguish endogenous and recombinant VEGF, and then cultured under both
hypoxic and normoxic conditions. After 15 hours, the culture media would be replaced
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with new media containing actinomycin D to inhibit new RNA synthesis and cells would
then be cultured under normal conditions. VEGF mRNA levels would then be
determined by northern blot, using a human VEGF165 specific probe, at time points up to
8 hours after the addition of actinomycin D. Changes in endogenous mRNA could be
used as a positive control. If VEGF165 mRNA levels are increased in cells cultured under
hypoxic conditions it would indicate that there is a putative hypoxia-regulatory element
within VEGF mRNA coding region. Further experiments could then be carried out to
determine the location of the regulatory region and the RNA binding proteins that bind it.
It would also be of interest to determine if increased healing with pVEGFE+ is
primarily mediated through an early increase in eNOS expression. In a rat model of
hindlimb ischemia Namba, et al. [163] demonstrated increased perfusion with
intramuscular injection of a plasmid encoding eNOS was mediated through VEGF. In
their study they inhibit eNOS activity by administering N(G)-nitro-L- arginine methyl
ester (L-NAME), a general inhibitor of nitric oxide synthase activity, through the animals
drinking water. Employing the same strategy, eNOS could be inhibited and RSF
perfusion and survival could be assessed. Effective inhibition of the VEGF-mediated
increase in eNOS should first be confirmed on the fourth POD, when the increase is first
seen, by ELISA. Although L-NAME is a general inhibitor of nitric oxide synthase
activity, and not eNOS specifically, these experiments would elucidate if inhibiting the
VEGF-mediated increase eNOS effects RSF healing.
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OPTIMIZATION OF DELIVERY CONDITIONS FOR THE MULTIELECTRODE ARRAY

Introduction

The design of the MultiElectrode Array (MEA) (Figure 11) expands on the
configuration of the 4PE. The MEA is composed of an array of 16 small electrodes, in a
4 by 4 configuration, with a 2-mm gap width between electrodes. Similar to the 4PE, the
design of the MEA allows for multiple sets of electrical pulses to be applied in 2 electric
field orientations at a 90° angle without removing the electrode from the delivery site.
One drawback to current electrode designs is that delivery of plasmid to a large surface
area requires the gap width between the electrode pairs to be increased thereby the
applied voltage must also be increased for cell permeabilization to be effective. The
design of the MEA allows for its dimensions to be expanded by incorporating a larger
number of electrode pairs thus enabling a larger
surface area to be treated without the need to
increase the distance between electrodes. Further,
the small gap width between the electrode pairs
decreases the depth of the electric field
penetration and thus should decrease the amount
Figure 11. The MultiElectrode
Array

of nerve stimulation and pain.
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The goal of the work presented in this chapter was to further evaluate and
optimize delivery parameters for the MEA. This work was completed using a plasmid
encoding the luciferase reporter gene (pLuc) delivered by intradermal injection in a
guinea pig model followed by in vivo EP with the MEA. Specifically, expression kinetics
and the effects of varying field strength, pulse duration, and plasmid dose were evaluated.

Results

Effect of field strength and pulse width on transgene expression

For in vivo EP, the voltage applied and pulse width are considered the main
determinants of the level of transgene expression, while other pulse parameters, such as
pulse number, have a lesser impact [65, 206]. Previous work determined that a field
strength of 300 V/cm and 150 ms pulse width applied with the MEA resulted in similar
luciferase expression levels achieved with the 4PE at 200 V/cm and 20 ms [Heller, R et
al., manuscript in preparation]. To further evaluate the effects of field strength and pulse
width for plasmid delivery with the MEA, 3 field strengths (300 V/cm, 250 V/cm and
225 V/cm) were examined with varying pulse widths, ranging from 350 ms to 50 ms
(Figure 12). Two days after plasmid delivery, the delivery sites were excised and
luciferase activity determined by a standard in vitro luciferase assay. For all 3 field
strengths and pulse widths, except for 250 V/cm, 50 ms pulses, there was a significant
increase in luciferase expression with pLucE+ compared to pLucE- (p< 0.001). In
general, a pulse duration of longer than 150 ms resulted in slightly higher levels of
luciferase expression, but 150 ms provided the highest level of expression with the least
variation and minimal visual damage to the delivery area.
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Figure 12. Effect of field strength and pulse width luciferase expression
Luciferase expression was determined 48 hours after delivery using an in vitro
luciferase assay for the indicated field strengths (V/cm) and pulse widths (ms). * p<
0.001 compared to pLucE-.
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Transgene expression kinetics

Because a pulse width of 150 ms for each of the field strengths examined in
Figure 12 (300 V/cm, 250 V/cm and 225 V/cm) resulted in the highest level of transgene
expression with the least variation and visible tissue damage, the duration of transgene
expression was then evaluated using all 3 field strengths with 150 ms pulses. There was
a significant increase in luciferase expression with all 3 field strengths beginning 24
hours after delivery. For 300 V/cm and 250 V/cm, luciferase expression remained
significantly higher than pLucE- through day 17 after delivery (Figure 13) (p< 0.001).
With all field strengths luciferase expression decreased to background levels 21 days
after delivery (data not shown). For 225 V/cm, luciferase expression remained
significantly higher with pLucE+ through day 10 after delivery (p< 0.001). Fourteen
days after delivery there was no significant increase in luciferase expression with 225
V/cm compared to pLucE- (p=0.103). However, on day 17 luciferase expression with
225 V/cm increased slightly and expression was significantly higher compared to pLucEat that time point (p< 0.001). Although there was a slight increase in expression on day
17 with 225 V/cm (3.4 x 105 photons / s) compared to day 14 (1.6 x 105 photons / s), the
significant difference on day 17 between pLucE+ and pLucE- for 225 V/cm is most likely
due to the decrease in luciferase expression with pLucE- on day 17 (3.8 x 104 photons / s)
compared to day 14 (1.2 x 105 photons / s). Luciferase expression for all field strengths
did not significantly decrease from the initial peak expression at 24 hours until day 10
after delivery (p< 0.001). In contrast, luciferase expression with pLucE- significantly
decreased 96 hours after delivery (p< 0.001).
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Figure 13. Luciferase expression kinetics
Luciferase expression was determined at the indicated time points by in vivo luciferase
assay for the indicated field strengths (V/cm) with 150 ms pulse widths. pLucE- and
225 V/cm n=16 per group per time point. 250 V/cm n=15 per group per time point.
300 V/cm n=14 per group per time point. * p< 0.001 compared to pLucE- for that time
point.
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Control of transgene expression by plasmid dose

Control over transgene expression levels is desirable for delivery of plasmids
encoding genes of therapeutic potential. As such, it was next determined whether a dose
response relationship existed between the amount of plasmid delivered and the resulting
level of transgene expression. A range of pLuc doses (20 µg, 50 µg, 100 µg, 150 µg and
200 µg) was delivered at 250 V/cm and 150 ms pulses. Two days after delivery,
luciferase expression was determined by in vivo luciferase assay (Figure 14). For
pLucE+, compared to 100 µg of pLuc (the dose delivered in Figures 12 and 13), a
significant decrease in luciferase expression was seen when delivering 20 µg of pLuc (p<
0.01) and a significant increase was seen when delivering 200 µg of pLuc (p< 0.01).
While altering the pLuc dose required altering the intradermal injection volume, varying
injection volume did not significantly affect transgene expression with pLucE+ (Figure
15).

50

Figure 14. Control of luciferase expression by plasmid dose
Luciferase expression was determined 48 hours after pLuc delivery by in vivo
luciferase assay. pLucE+ = 250 V/cm 150 ms. For 20 µg, 150 µg and 200 µg, n=6 per
group for both pLucE- and pLucE+; For 100 µg n=8 per group for both pLucE- and
pLucE+; For 50 µg pLucE- n=6 and pLucE+ n=5. * p< 0.05 for that plasmid dose, ‡ p<
0.05 compared to expression with pLucE+ delivering 100 µg.
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Figure 15. Increasing plasmid injection volume does not affect luciferase
expression
Luciferase expression was determined using an in vivo luciferase assay 48 hours after
delivery of 100 µg pLuc in the indicated injection volume. pLucE+ = 250 V/cm, 150
ms. n=8 per group. * p< 0.001 compared to pLucE- for that injection volume.
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Discussion

As a whole, the data presented in this chapter demonstrate that the level and
duration of transgene expression achieved for pLucE+ delivered with the MEA can be
adjusted by altering either electroporation parameters or plasmid dose. The duration and
magnitude of the voltage applied has a significant impact on the level of
electropermeabilization of the cell membrane in the target tissue [206]. Delivery of pLuc
at 300 V/cm, compared to 250 V/cm and 225 V/cm, resulted in slightly higher luciferase
expression at all pulse widths examined, but there was frequently visible tissue damage
after delivery. It is possible that damage to the tissue is the reason for increased
variability with 300 V/cm. Compared to 225 V/cm, luciferase expression was higher
with 250 V/cm at all pulse widths. The lack of a significant increase in luciferase
expression with 50 ms pulses delivered at 250 V/cm (Figure 12) indicates that 100 ms
may be the minimum pulse duration to reach the necessary level of cell membrane
permeabilization to increase plasmid uptake at a field strength of 250 V/cm or less.
The results presented in Figure 12 utilized in vitro luciferase assays to evaluate
transgene expression. In vivo bioluminescense imaging allows for the use of fewer
experimental animals and was used to determine luciferase expression in Figures 13, 14
and 15. Prior to using in vivo luciferase assays, it was determined that the results
obtained by the in vivo assay were highly correlated with the results obtained by the in
vitro assay (r2= 0.94, n=8).
It was previously reported [200] transgene expression decreases 3 days after
plasmid DNA delivery by intradermal injection [200]. Consistent with these findings, in
this study luciferase expression with pLucE- significantly decreased between days 3 and
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4 after delivery compared to the initial peak expression at 24 hours (Figure 12). For all
pLucE+ conditions, there was a significant decrease in luciferase expression 10 days after
delivery, compared to the initial peak at 24 hours, and expression with 300 V/cm and 250
V/cm remained greater than pLucE- for 17 days. Luciferase expression with 225 V/cm
was not significantly greater then pLucE- 14 days after delivery, but on day 17
expression with 225 V/cm slightly increased and was significantly higher than expression
with pLucE+. The significant difference in expression with 225 V/cm, compared to
pLucE-, at day 17 is most likely due to the decrease in luciferase expression with pLucE-.
Also, 225 V/cm resulted in an overall lower level of luciferase expression then 300 V/cm
and 250 V/cm beginning at day 10 after delivery. Preliminary data not reported here
determined that a field strength of 200 V/cm and 100-150 ms pulses increases luciferase
expression approximately 2-fold compared to pLucE- 2 days after delivery. Overall,
these results indicate that if a lower level of expression is desired, it could be achieved by
decreasing the field strength.
Adjusting the level of transgene expression can also be accomplished by
increasing or decreasing the dose of plasmid delivered. Compared to delivery of 100 µg
pLuc (7.3 x 108 photons / s), delivery of 200 µg (4.5 x 109 photons / s) resulted in a 6-fold
increase and delivery of 20 µg a 3.4-fold decrease (2.1 x 108 photons / s) in luciferase
expression. Luciferase expression continued to increase up to 200 µg of pLuc and there
was a linear correlation between the amount of plasmid delivered and luciferase
expression (r2= 0.88) indicating the maximum expression level was not reached. Further
experiments will be needed to determine the dose required to achieve the maximum level
of expression.
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In summary, for pLucE+, the level of luciferase expression increased with the
magnitude of the voltage applied. For each of the field strengths examined, a pulse
duration of 150 ms achieved the highest level of expression with the least variation and
visible tissue damage. Also, for all 3 field strengths, luciferase expression did not
decrease from initial peak expression at 24 hours until 10 days after delivery and with
300 V/cm and 250 V/cm remained significantly higher than pLucE- for at least 17 days.
In addition to adjusting transgene expression levels by altering fielding strength, levels
can also be controlled by adjusting the plasmid dose.

Future directions

While the MEA was designed for plasmid delivery to the skin, it may also be a
useful non-penetrating electrode design for the delivery of plasmid to other tissues.
Plasmid DNA can be delivered to internal organs using both penetrating (needle arrays)
and non-penetrating electrodes. Generally, if a non-penetrating electrode design is
selected to deliver plasmid DNA to internal organs, such as the liver, in vivo EP would be
carried out with a paddle electrode. The concerns with this approach are similar to those
when delivering plasmid to the skin with the caliper electrode. In order to apply 2 sets of
pulses, the electrode plates need to be manipulated around the treatment site, and removal
and replacement of the electrode plates results in variation in the distance between the
plates and thus a variation in the applied voltage. The design of the MEA would
eliminate this variation. In addition to being effective for plasmid delivery to the skin,
the MEA has already been shown to be effective for in vivo EP plasmid delivery to
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cardiac muscle [Marshall, WG et al., submitted for publication] and could easily be
explored for delivery to other organs, such as the liver.
Experiments optimizing delivery conditions for the MEA were initially planned to
be carried out in a hairless guinea pig model because the structural characteristics and
vascularity of hairless guinea pig skin closely resemble human skin [207, 208].
Unfortunately, hairless guinea pigs were not available at the time these experiments were
completed or for the foreseeable future. Confirmation of the data presented here,
generated in Hartley guinea pigs, in the hairless guinea pig, if available, would be helpful
when moving this technology into clinical trials. If hairless guinea pigs are not available
then confirmation of this data in a porcine model, which also have skin similar to human
skin [200], would be an alternative option.
The MEA was designed to allow for its dimensions to be expanded by
incorporating a larger number of electrode pairs to treat a larger surface area without the
need to increase the distance between electrodes. While the data presented here confirms
the principle of the MEA design, experiments employing a larger electrode (composed of
more electrode pairs) than the one utilized in these experiments have not yet been
completed. A further understanding of the expression levels and kinetics that can be
achieved with a larger MEA would be useful for future studies and for translation into
clinical applications.
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INTRADERMAL DELIVERY OF PLASMID FGF-2 BY ELECTROPORATION INCREASES
PERFUSION AND ANGIOGENESIS IN AN ISCHEMIC HINDLIMB

Introduction

Gene therapy approaches delivering plasmid FGF-2 by intramuscular injection of
plasmid FGF-2 alone [209] or followed by intramuscular in vivo EP [210, 211] have
shown promise as a treatment for PAD in preclinical models. Also, delivery of
recombinant FGF-2 has been shown to be beneficial in patients with PAD in clinical
trials [178-180]. Currently, a simple non-invasive technique to deliver plasmid FGF-2 is
not available. The primary focus of the research presented in this chapter was to
determine if delivery of a plasmid encoding human FGF-2 (pFGF) to the skin with the
MEA would increase FGF-2 expression, blood flow, and angiogenesis in a rat model of
hindlimb ischemia. In addition, this was the first study utilizing the MEA to deliver a
plasmid encoding a gene with therapeutic potential and expression levels were compared
to those achieved with the 4PE.

To create the rat model of hindlimb ischemia, the most distal end of the external
iliac artery and the femoral artery proximal and distal to the bifurcation of the superficial
epigastric artery and vein were ligated. The femoral artery was then cut between the
ligation of the external iliac, adjacent to the inguinal ligament, and dissected free to the
bifurcation of the superficial artery and vein (Materials and Methods for complete
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description). This method of inducing hindlimb ischemia, the ligation and excision
method, effectively decreased blood flow to the limb at rest for the duration of the study
(14 days) and is considered an appropriate model to study potential therapies for CLI
[147, 155-157]. After postoperative perfusion assessment with LDPI, pFGF was
delivered to the ischemic hindlimb at 2 sites on the medial aspect of the ischemic limb by
intradermal injection followed by EP with the MEA.

Results

In vitro plasmid FGF-2 expression

The ability of pFGF to increase FGF-2 expression was tested in vitro prior to use
in vivo. The promoter and coding region of FGF-2 was removed from pBLAST-bFGF
and cloned into the backbone of the pVAX1 to allow for more efficient preparation of
large quantities of the plasmid. The level of FGF expression with pFGF was slightly
lower compared to pBLAST-bFGF, but pFGF still effectively increased FGF-2
expression. As expected, FGF-2 was detected in the cell lysate and not the cell culture
supernatant because FGF-2 is only secreted from cells during active angiogenesis [212]
(Figure 16).
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Figure 16. In vitro pFGF expression
Average FGF-2 expression ± SD was determined by ELISA 48 hours after lipidmediated transfection of HaCat cells with pFGF, pBLAST-bFGF or the pVAX1 vector
backbone without a cDNA insert. pFGF n=3 pBLAST-FGF-2 n=1, pVAX1 n=1.

Optimization of electroporation conditions for plasmid FGF-2 delivery

The work described in the previous chapter utilized a reporter plasmid (pLuc) in a
guinea pig model to evaluate delivery conditions for the MEA. It was expected that
delivery of a plasmid encoding a gene of therapeutic potential (pFGF) in a different
animal model would result in different expression kinetics. Thus, it was next evaluated
whether pFGFE+ delivered with the MEA increased FGF-2 expression in the skin of the
rat flank and if the level of expression achieved was similar to that achieved when
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delivered with the 4PE. Two days after pFGFE- or pFGFE+, skin samples from the
delivery sites were excised and assayed for FGF-2 expression by ELISA (Figure 17). The
level of FGF-2 expression was approximately equal for pFGFE+ delivered with the 4PE
at 200 V/cm, 20 ms (4,763 ± 1,105 pg / sample) and the MEA at 250 V/cm, 150 ms
(4,257 ± 815 pg / sample). FGF-2 expression was slightly greater when pFGF was
delivered with the MEA at 300 V/cm, 150 ms (5,482 ± 901 pg / sample).

Figure 17. Comparison of FGF-2 expression after pFGF delivery with the
4PE or MEA
FGF-2 expression was determined by ELISA 48 hours after delivery of pFGF to the
rat flank with either the 4PE or MEA at the indicated field strengths and pulse widths.
n=4 per group. Average expression ± S.D. is reported. * p< 0.02 compared to pFGFE-.
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FGF-2 expression kinetics

The duration of FGF-2 expression was next determined for pFGFE+ delivered at
300 V/cm, 150 ms with the MEA. At the time points indicated in Figure 18, skin from
the treated areas were excised and assayed for FGF-2 expression by ELISA. For 10 days
after plasmid delivery pFGFE+ significantly increased FGF-2 protein levels compared to
pFGFE- (p< 0.05) before decreasing to background levels at days 14 and 17 after
delivery. The application of an electric field to tissues alone can transiently induce
expression of some genes, including angiogenic growth factors [186-188], however,
pVAXE+ resulted in similar levels of FGF-2 expression as P-E- (n=4, 1416 ± 326 total
pg / sample).

Plasmid FGF-2 with electroporation increases blood flow in the ischemic hindlimb

It was next evaluated whether the pFGFE+ treatment could increase blood flow in
a rat model of hindlimb ischemia. Immediately postoperatively, pFGFE+ or control
treatments were administered at 2 sites on the medial aspect of the ischemic limb. LDPI
was used to measure blood flow in the distal area of both the ischemic and non-ischemic
limbs preoperatively (baseline), immediately postoperatively and on PODs 1, 3, 7, and 14
(Figure 19a). Immediately postoperatively, perfusion decreased to approximately 40% of
baseline indicating the hindlimb was effectively rendered ischemic. In Figure 19b blood
flow is reported for each treatment group as the ratio of blood flow in the ischemic
hindlimb to the non-ischemic hindlimb (I/NI) (Figure 19b, top panel) and as a percent of
the perfusion recorded at baseline (Figure 19b, bottom panel). There was significant
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Figure 18. FGF-2 expression kinetics
At the indicated time points, skin samples were harvested from the delivery sites
and assayed for FGF-2 protein expression by ELISA. To determine FGF-2
expression resulting from pFGFE+ and pFGFE- the average FGF-2 expression in
untreated skin (n=4, 1416 ± 326 total pg / sample) was subtracted from the total
pg/sample determined for each treatment site. Day 2 n=10, days 4, 7, and 10 n=6
and days 14 and 17 n=8 per group per time point. pFGFE+= 300 V/cm, 150 ms. **
p< 0.01, * p< 0.05.

difference in limb blood flow beginning on the third POD between all treatment groups
for I/NI (p< 0.02) and as a percentage of baseline blood flow (p< 0.001). Also on POD 3,
blood flow in the pFGFE+ treatment group was significantly greater than all of the
control groups for I/NI and percentage of baseline blood flow (p< 0.001). Perfusion in
the ischemic limb continued to be higher in the pFGFE+ treatment group compared to the
control treatment groups for all subsequent time points in the study (p< 0.05, all time
points for I/NI and percent of baseline blood flow). The pFGFE- treatment group showed
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a slight, but not significant, increase in perfusion compared to the pVAXE+ and P-Etreatment groups on PODs 7 and 14.

Figure 19a. pFGFE+ increases hindlimb blood flow
Representative LDPI images of the ischemic limb from the pFGFE+ and pFGFEtreatment groups at baseline and on PODs 0, 3, 7 and 14. As indicated in the color
legend on the right, areas red or white in color represent higher perfusion and areas in
blue lower perfusion. The white box indicates the approximate area where perfusion was
assessed. The black arrows indicate the absence of perfusion in the area of the femoral
artery after the operation to induce hindlimb ischemia.
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Figure 19b. pFGFE+ increases hindlimb blood flow
Perfusion was determined by LDPI. (Top) Ratio of perfusion in the ischemic limb to the nonischemic limb (I/NI) for all treatment groups. (Bottom) Postoperative perfusion at the
indicated time points relative to baseline perfusion for all treatment groups. Percent of
baseline perfusion was calculated using the I/NI determine during the baseline perfusion
measurements. n=6 per group per time point. * p< 0.05 compared to all controls.
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Plasmid FGF-2 with electroporation increases angiogenesis in the ischemic hindlimb

Next, it was determined whether the increase in limb perfusion in the pFGFE+
treatment group resulted from an increase in angiogenesis. In rodent models of hindlimb
ischemia, as well as in patients with PAD, angiogenesis typically occurs in the
gastrocnemius muscle, or distal to the arterial occlusion, while arteriogenesis occurs
higher in the limb near the site of the occlusion [147, 213]. Thus, on POD 14 samples
were harvested from the gastrocnemius muscle of the ischemic limb and capillary density
was visualized by immunohistochemical staining for the endothelial cell marker factorVIII associated antigen. Representative fields (400X) from each of the 4 treatment
groups are shown in Figure 20. Also in Figure 20, the average number of vessels in 5
randomly selected high power fields (HPFs) (400 X) for 5 animals in each treatment
group is reported. There was approximately a 2-fold increase in capillary number in the
pFGFE+ treatment group compared to all control groups (p< 0.001) indicating the
increase in perfusion to the ischemic limb with pFGFE+ was in fact due to an increase in
angiogenesis.
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Figure 20. pFGFE+ increases angiogenesis in the ischemic hindlimb
(Left) Representative cross-sections (400X) of Factor VIII immunohistological staining of
samples excised from the gastrocnemius on POD 14. (Right) quantification of capillary
density. The average number of capillaries in 5 fields, for 5 animals in each treatment
group. * p< 0.01 compared to all controls.
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Discussion

In addition to direct injection of naked plasmid DNA, the most prevalent methods
of FGF-2 delivery documented in the literature are viral-mediated gene transfer and
recombinant protein injection. These methods are promising for treatment of PAD but
have draw-backs (See General introduction, Methods of therapeutic gene delivery).
Further, the unregulated expression and long term expression conferred by some viral
vectors, relative to plasmid DNA vectors, increases the possibility of the occurrence of
the adverse side-effects associated with high levels of FGF-2 expression, such as
potential toxicity and proteinuria [140, 214]. In both animal models [21, 215, 216] and
clinical trials [178-180], intramuscular injection or intra-arterial administration of
recombinant FGF-2 protein improved perfusion to the ischemic limb or PAD related
symptoms, respectively. Similar to VEGF, the use of recombinant FGF-2 in a clinical
setting is not practical due to its short half-life and poor bioavailability. Consequently
frequent administration of the recombinant protein is often required to sustain lasting
effects [37, 38, 140].
The strategy presented here is a simple, non-invasive approach that effectively
increases FGF-2 protein expression, ischemic limb blood flow and angiogenesis. FGF-2
expression was similar for pFGFE+ delivered with the 4PE and MEA (Figure 17) and
was significantly higher with pFGFE+ than pFGFE- for at least 10 days after delivery
(Figure 18). Beginning on POD 3, there was a significant difference in blood flow in the
ischemic hindlimb among all treatment groups, and blood flow in the pFGFE+ treatment
group was significantly greater than all control groups (p< 0.05). The increase in
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hindlimb perfusion with pFGFE+ treatment persisted from POD 3 through POD 14, the
end point of the study (Figure 19b). There was also a significant increase in the number
of capillaries in the gastrocnemius muscle with pFGFE+ treatment indicating the increase
in limb blood flow is, a least in part, the result of an increase angiogenesis (Figure 20)
(p< 0.001).
The increases in perfusion and angiogenesis in the pFGFE+ treatment group may
be occurring by several known in vivo mechanisms. FGF-2 is normally confined to the
cell compartment but during active angiogenesis it is exported to the extracellular space
to exert downstream effects [28]. Therefore, although pFGFE+ treatment is administered
to the skin, increased levels of FGF-2 protein after treatment and subsequent export could
activate downstream angiogenic pathways. For example, a recent study by Fujii, et al.
[209] demonstrated that in a model of hindlimb ischemia intramuscular injection of a
plasmid encoding FGF-2 increased the expression of placental growth factor via the
upregulation of VEGF expression. Placental growth factor alone is known to increase
angiogenesis in models of hindlimb ischemia, and it is possible a similar mechanism may
be occurring with pFGFE+ [217, 218]. Another possible mechanism for the increase in
angiogenesis and hindlimb blood flow with pFGFE+ treatment is the upregulation of
HGF. FGF-2 stimulates HGF expression, which itself has also been successful in
increasing perfusion in preclinical models [165, 166] and in a clinical trial [167].
Determination of the exact mechanism of pFGFE+ mediated angiogenesis will require
further studies.
In summary, electrically-mediated intradermal delivery of pFGF is a potential
non-invasive non-viral therapeutic approach to increase perfusion and angiogenesis in a
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hindlimb ischemia model and warrants further investigation as a possible treatment for
PAD.

Future Directions

Unlike humans, the rat has an abundant network of collateral vessels in the lower
limbs due to the physiological absence of the profunda femoris artery [151]. Prior to
investigating this approach as a potential therapy for limb ischemia in the clinic, it should
be further tested in a larger animal model with a vascular anatomy that more closely
resembles that of humans, such as the rabbit or swine [147]. If pFGFE+ is explored as a
potential treatment for PAD in a larger animal model, the field strength and pulse width
should first be optimized for that animal model. In this study, a lower field strength was
used for pFGF delivery to the hindlimb (250 V/cm, 150 ms) to achieve FGF-2 expression
levels that were comparable to the levels observed after pFGF delivery to the flank at a
higher field strength (300 V/cm, 150 ms). Relative to the skin of rat flank, the skin of the
hindlimb is markedly thinner. Therefore, it is expected that a higher field strength would
be required to achieve equivalent expression in a larger animal model, such as the swine,
with thicker skin than that of the rat hindlimb.
Optimally, both angiogenesis and arteriogenesis should be stimulated to increase
perfusion to the lower limb [144, 219]. At the time these experiments were carried out,
the technology used to assess collateral vessel formation in a small animal model was not
available. When moving this approach to a larger animal model, it would also be
beneficial to determine if pFGFE+ increases arteriogenesis in addition to angiogenesis.
Gross observation of the skeletal muscle in the ischemic limbs on POD 14 of this study
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suggested there may be an increase in arteriogenesis with pFGFE+ as indicated by the
healthier color of the muscle and the presence of superficial immature collaterals
identified by an increase in calibres and their typical corkscrew pattern [5]. The presence
of immature collaterals would be expected as a result of inducing ischemia in the
hindlimb alone, and therefore, is not necessarily indicative of pFGFE+ increasing
collateral vessel growth.
In this study, pFGFE+ increased blood flow in the ischemic hindlimb, but the
mechanism was not defined. One possible pathway for FGF-2 to increase blood flow and
angiogenesis is through the upregulation of VEGF. Other studies have shown in models
of hindlimb ischemia that delivery of exogenous FGF-2 increases VEGF expression and
that blocking VEGF abrogates the therapeutic effects of FGF-2 [21, 209]. Future studies
could be conducted using a VEGF neutralizing antibody to block endogenous VEGF
expression, similar to those conducted by Masaki et al. [21], to determine if pFGFE+
mediates its therapeutic effects through VEGF. Briefly, a VEGF neutralizing antibody
would be administered the same day as pFGFE+ treatment, hindlimb perfusion would be
monitored through POD 14 and capillary density would be determined in gastrocnemius
muscle samples excised at the end point of the study. Successful neutralization of
endogenous VEGF expression, and the duration of the neutralizing effects of the
antibody, should first be determined in tissue samples from the gastrocnemius muscle
using a VEGF ELISA. If pFGFE+ exerts its angiogenic effects by upreguating VEGF,
perfusion and capillary density should be similar in the pFGFE+ group receiving the
VEGF neutralizing antibody and the pVAXE+ and P-E- control groups.
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The skin is an attractive target for transgene delivery with in vivo EP because it is
easily accessible and thus frequency and / or number of treatments can be easily
increased. For delivery to the rat hindlimb (250 V/cm, 150 ms) and the flank (300 V/cm,
150 ms), pFGFE+ increased FGF-2 expression approximately 2-fold compared pFGFE-.
This increase was sufficient to induce a biological effect, but it would be of interest to
evaluate if treatment at more than 2 sites on the ischemic hindlimb or if increasing the
plasmid dose would further increase limb perfusion and neovascularization. Of note, the
observed increase in FGF-2 with pFGFE+ may have been diminished by the presence of
high levels of endogenous FGF-2 in the rat skin (1416 ± 326 total pg / sample). The skin
of the medial aspect of the hindlimb is exceptionally thin and increasing the field strength
above 250 V/cm resulted in visual tissue damage. Thus, increasing the field strength is
not a viable option to increase FGF-2 expression with pFGFE+ treatment in the rat model
of hindlimb ischemia and increasing the dose of plasmid and number of treatments
should be further explored. As mentioned above, increasing the field strength will likely
be necessary to increase the level of FGF-2 expression achieved with pFGFE+ in a larger
animal model. Also, in a larger animal model with thicker skin, a larger range of EP
parameters could be examined and it is possible that increasing the field strength or pulse
width would result in a larger fold-increase in FGF-2 expression with pFGFE+, compared
to pFGFE-.
The establishment of new functional vascular networks is a complex process
orchestrated by a myriad of growth factors and cytokines. Transfer of a single
angiogenic growth factor or cytokine has shown promise in preclinical and clinical
studies, but the efficacy of these therapeutic approaches may be improved by delivering a
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combination of angiogenic growth factors and / or cytokines. An elegant study by Cao,
et al. determined that delivery of both FGF-2 and PGDF-ββ to a rat and rabbit model of
hindlimb ischemia synergistically increases neovascularization [215]. Synergistic
increases in neovascularization have also been observed with combined delivery of FGF2 and VEGF in rabbit [220] and mouse[211] models of hindlimb ischemia. The
combination of FGF-2 with HGF has also been shown to synergistically increase
neovascularization more than either growth factor alone in a mouse model of hindlimb
ischemia [221]. pVEGFE+ and pVEGFE- did not increase VEGF expression above
background levels in this or a more severe hindlimb ischemia model (data not shown).
Despite the decrease in blood flow to the muscles of the ischemic limb, the skin most
likely remained normoxic and did not allow for VEGF mRNA stabilization and
expression. If the combination of FGF-2 and VEGF were to be explored, VEGF could be
delivered to the gastrocnemius muscle while still delivering pFGFE+ to the skin of the
ischemia limb, but the potential treatment would no longer be non-invasive. Future
experiments exploring if pFGFE+ in combination with a plasmid encoding PDGF-ββ or
HGF increases limb blood flow more than either treatment alone would be useful for
moving this approach toward clinical trials, especially if the experiments were conducted
in a larger animal model as suggested above.
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MATERIALS AND METHODS

Plasmids

The CMV promoter was removed from the pVAX1 plasmid (Invitrogen) to create
a promoterless pVAX1. The human VEGF165 plasmid was cloned by sub-cloning the
hEF1-HTLV-hVEGF165 sequence from pBLAST49-hVEGF (Invivogen) into the
promoterless backbone of pVAX1. The human FGF-2 plasmid (pFGF) was cloned by
sub-cloning the hEF1-IF4g-hbFGF sequence from pBLAST45-hbFGF2 (Invivogen) into
the promoterless backbone of pVAX1. The luciferase plasmid used in this research was
gWiz-Luc (Aldevron). For in vivo use, all plasmids were commercially prepared
(Aldevron).

Cell culture and transfection

Experiments confirming in vitro expression of pVEGF were performed using the
B16F10 mouse melanoma cell line maintained in McCoy's Media 5A with 10% FBS and
0.2% Gentamycin. In vitro expression of pFGF was confirmed in the immortalized
keratinocyte HaCaT cell line maintained in DMEM media with 10% FBS and 0.2%
Gentamycin. Twenty-four hours prior to transfection, 2 x 105 cells were plated per well
in 6-well cell culture dishes. Cells were transfected with 2.5 μg of plasmid per well using
the TransIT-LT1 Reagent (Mirus) according to manufacturer’s instructions. Forty-eight
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hours after transfection cells were harvested and lysed in 100 μl of lysis buffer (150 mM
NaCl, 20 mM sodium phosphate pH 7.4, 10% glycerol, 1% NP-40 and protease inhibitors
(Roche)) for 30 min on ice. Lysates were then centrifuged at 4C for 10 minutes at
10,000 rpm and protein expression determined by ELISA.

Animals and anesthesia

All procedures were approved by the Animal Use and Care Committee of the
University of South Florida College of Medicine. Male Sprague Dawley rats (250-300 g)
(Harlan) were used for both the RSF model and hindlimb ischemia model. Female
Hartley guinea pigs (250-300 g) were purchased from Charles River. Prior to operations
and all procedures, animals were placed in an induction chamber and anesthetized with
5% isoflurane in oxygen. After the animals were anesthetized they were fitted with a
standard rodent mask and maintained under anesthesia with 3.0% isoflurane in oxygen.
All operations were performed using standard aseptic technique. At indicated time points
animals were humanely euthanized by exposure to CO2.

The random skin flap model

To create the rostral-based single pedicle RSF on the left lateral flank, the rat was
shaved and an 8-cm by 3-cm template was traced with a surgical marker. Full thickness
incisions were made along the traced template lines. The skin and subcutaneous tissue
were then elevated and sutured back to its bed using simple interrupted and running
stitches with 4-0 non-absorbable sutures.

74

The hindlimb ischemia model

Hindlimb ischemia was induced in right hindlimb of the Sprague Dawley rats.
Through an approximately 2-cm long incision parallel to the inguinal ligament the
saphenous artery was ligated distally of the bifurcation of the femoral artery into the
saphenous and popliteal arteries. The most distal end of the external iliac was ligated
immediately adjacent to the inguinal ligament and the femoral artery was ligated
proximal and distal to the bifurcation of the superficial epigastric artery and vein. The
superficial epigastric artery and vein were also ligated at 2 sites adjacent to the femoral
bifurcation and cut between these sites. The femoral artery was then cut between the
ligations adjacent to the inguinal ligament and distally of the superficial epigastric artery
and vein. The femoral artery was then dissected free from the point of the distal ligation
of the saphenous artery to the ligation of the femoral placed distally to the bifurcation of
the superficial artery and vein.

In vivo electroporation
For all in vivo experiments, all plasmids were at a concentration of 2 µg/μL in
sterile injectable saline and all injections were 50 µL in volume unless otherwise noted.
All injections were performed using a 25 gauge, 5/8-inch length needle.

Plasmid delivery to muscle

The rat gastrocnemius muscle was exposed using a 1-cm incision. pVEGF was
then injected into the center of the muscle and the injection site marked with a single
stitch using a 4-0 non-absorbable suture to later identify the delivery site to be excised for
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protein extraction. For pVEGFE+, a 4-needle electrode array, with a 6-mm gap width
between needles, was then placed around the delivery site and 8 20 ms pulses were
delivered at 200 V/cm.

Plasmid delivery to skin

For delivery to the RSF with the 4PE: Injections were centered along the midline
of the RSF at 1, 3, 5, and 7-cm from the pedicle. Injection sites were marked with a
surgical marker if they were to be excised later for protein extraction. Where noted,
proximal delivery sites were placed at 1-cm and 3-cm from the RSF pedicle and distal
delivery sites were placed at 5-cm and 7-cm from the RSF pedicle. After injection of
plasmid DNA, the 4PE [68] was used to deliver 8 20 ms electric pulses at 200 V/cm to
pVAXE+ and pVEGFE+ treatment groups. For delivery of pLuc to guinea pig skin with
the MEA: Plasmid was intradermally injected at sites on the guinea pig flank. The MEA
was then placed over the injection bubble and an electric field applied at the indicated
field strengths and pulse widths. Delivery sites were marked with a surgical marker for
later identification for quantification of luciferase expression. For delivery of pFGF with
the MEA: pFGF was delivered to 2 sites on the medial aspect of the ischemic hindlimb
immediately after assessment of postoperative perfusion. After injection of plasmid
DNA, the MEA was placed over the injection bubble and 150 ms pulses were applied at
300 V/cm (delivery to skin of rat flank for initial expression kinetics) and 250 V/cm
(delivery to hindlimb). FGF-2 expression levels from pFGFE+ and pFGFE- were
equivalent at 300 V/cm for delivery to the rat flank and 250 V/cm for delivery to the
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hindlimb. FGF-2 expression with pFGFE+ and pFGFE- did not differ between the
ischemic and non-ischemic hindlimb.

In vitro luciferase assays

At the indicated time points animals were humanely euthanized and the delivery
sites were excised and snap frozen on dry ice. Tissue samples were homogenized in 1 to
2 mL of homogenization buffer (25 mM Tris, pH 7.8, 2 mM EDTA, 1 mM DTT and 10%
glycerol). Homogenates were then centrifuged at 4°C for 2 minutes and the supernatants
were removed and assayed for luciferase activity in Luciferase Assay Buffer (25 mM
glycylglycine, pH 7.8, 15 mM KPO4, pH 7.8, 15 mM MgSO4, 4 mM EGTA, 2 mM ATP,
1 mM DTT and 100 µM Luciferin). Luciferase activity was quantitated using a MLX
microtiter plate luminometer (Dynex Technologies). Using a standard preparation of
recombinant luciferase (Promega) relative light unit values were converted to pg of
luciferase and luciferase activity is reported as total pg luciferase per tissue sample.

In vivo luciferase assays

In vivo bioluminescence imaging was completed using the IVIS 100 system
(Xenogen Corp.) in conjunction with the Living Image acquisition and analysis software
(Xenogen Corp.). Luciferin (Xenogen Corp.) was dissolved to 7.5 mg/ml in PBS, filtersterilized, and stored in single use aliquots at -20°C. At the indicated time points the
guinea pigs were anesthetized and received a 50 µL intradermal injection of Luciferin
solution at the delivery site. Images were acquired 2 minutes after Luciferin injection.
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Quantitation of luciferase activity was based on the total flux (photons / sec) of emitted
light from the delivery site.

Determination of protein expression

At the indicated time points the delivery sites were excised and snap frozen on dry
ice. Tissue samples were homogenized in 1 to 2 mLs of lysis buffer (150 mM NaCl, 20
mM sodium phosphate pH 7.4, 10% glycerol, 1% NP-40 and protease inhibitors
(Roche)). Homogenates were then centrifuged at 4C for 10 minutes at 10,000 rpm. The
supernatants were removed and assayed for protein expression using commercially
available ELISAs for human VEGF165 (R&D Systems, DY293B), eNOS (R&D Systems,
DEN00) and FGF-2 (R&D Systems, DY233) according to the manufacturer’s
instructions.

Laser Doppler Perfusion Imaging

A Laser Doppler Perfusion Imager (Moor Instruments Ltd.) was used to record
perfusion at the indicated time points. A low intensity (2 mW) laser light beam (λ= 632.8
nm) scanned the surface of the skin without contact at a standardized working distance of
28 cm. Scan modus was set at 10 ms/pixel and resolution at 256 x 256 pixels. To control
for variability that may result from fluctuations in temperature and ambient light, animals
were placed on a heating pad and measurements were completed in a low lit room.
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Random skin flap model

Three scans were completed per time point for each animal and average perfusion
in arbitrary units (flux) for the distal region of the skin flap (5-cm2 area) was determined
for each time point. Baseline perfusion was assessed immediately preoperatively and
postoperative perfusion was assessed immediately after the operation to create the RSF.
Perfusion results are reported as the percentage of perfusion units relative to baseline or
postoperative perfusion (normalized to 100%).

Hindlimb ischemia model

Three scans were completed per time point for each animal for both the ischemic
and non-ischemic limbs and average perfusion in arbitrary units (flux) was determined
separately for each limb. Perfusion in the ischemic limb was normalized to the contralateral non-ischemic limb to minimize variation due to ambient light and temperature.
Baseline perfusion was assessed immediately preoperatively and postoperative perfusion
assessed immediately after completion of the operation to induce hindlimb ischemia. The
average I/NI was used to calculate percentage of baseline perfusion at the postoperative
time points.

Assessment of skin flap healing
The percent survival of the distal 5-cm2 area of the RSF was quantitated on PODs
7 and 14. Areas dark in color and / or covered in scabs were defined as necrotic / nonsurviving areas. Areas with normal skin texture and color were defined as surviving
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areas. The surviving areas were calculated using the Moor imaging software (Moor
Instruments Ltd.) and images were recorded using a digital camera (Nikon).

Histology

On POD 14 animals were humanely euthanized. Tissue samples were excised 2cm from the distal end in the center of the RSF, fixed in 10% neutral buffered formalin
for at least 12 hours at room temperature, embedded in paraffin and sectioned (4-μm). If
the tissue was necrotic at 2-cm from the distal end, samples were excised at the border of
the necrotic and surviving tissue. Sections were then stained with H&E using a standard
protocol. Stained sections were analyzed using a standard light microscope (Olympus
BX51) and representative fields photographed with a Spot Insight 2 digital camera
(Pathtech).

Immunohistochemistry

On POD 14 animals were humanely euthanized and tissue samples from the
gastrocnemius muscle were excised and fixed in 10% neutral buffered formalin for at
least 12 hours at room temperature before embedding in paraffin and sectioning (4-μm).
Capillaries in the cross-sections were visualized using the Blood Vessel Staining Kit
(Chemicon) according to manufactures instructions for Factor VIII with Hematoxylin
counterstaining. The number of Factor VIII positive vessels was manually counted in a
blinded fashion in 5 randomly selected fields (400X) for 5 animals from each treatment
group. Stained sections were analyzed using a standard light microscope (Olympus
BX51). The average capillary density per HPF (400X) for each treatment group is
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reported. Representative fields from each treatment group were photographed at 400X
with a digital camera (Spot Insight 2).

Statistical Analysis
All values are reported as the mean  SEM unless otherwise noted. Statistical
significance was assumed at p≤ 0.05. All statistical analysis was completed using the
Statistical Package for the Social Sciences (SPSS).
Analysis of VEGF expression was completed using a 2-tailed Student’s t-test.
Analysis of eNOS expression and distal RSF perfusion was completed using ANOVA
with a post-hoc Dunnett’s test to adjust for multiple comparisons to a single control group
(pVEGFE+). Analysis of distal RSF survival was completed using the Mann-WhitneyWilcoxon test with a post-hoc Bonferroni-Dunn correction to adjust for multiple
comparisons. Analysis of luciferase activity was completed using a 2-tailed Student’s ttest when comparing 2 groups. Analysis of 3 or more groups was completed by ANOVA
with a post-hoc Fisher’s Least Significant Difference adjustment for multiple
comparisons. Analysis of FGF-2 expression and capillary density in the ischemic
hindlimb was completed using a 2-tailed Student’s t-test. A post-hoc Bonferroni
correction was used to adjust for multiple comparisons to pFGFE+ for analysis of
capillary density. Analysis of hindlimb perfusion was completed by ANOVA with posthoc Fisher’s Least Significant Difference adjustment for multiple comparisons.
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